New molecular strategies for prevention of fibroproliferative vascular disease : An experimental approach to restenosis by Tigerstedt, Nina-Maria
 
 
 
 
 
 
 
 
 
 
 
 
 
Helsinki University Biomedical Dissertations No. 115 
 
 
 
 
New molecular strategies for prevention of 
fibroproliferative vascular disease 
- An experimental approach to restenosis 
 
 
 
Nina-Maria Tigerstedt, MD 
 
 
Transplantation Laboratory, University of Helsinki and  
Helsinki University Central Hospital,  
Helsinki, Finland. 
 
 
 
 
 
ACADEMIC DISSERTATION 
 
To be publicly discussed with the permission of the Medical Faculty of the University of 
Helsinki in the Small Auditorium, Haartman Institute, on February 27th 2009, at 12 noon. 
 
 
Helsinki 2009 
 
 
 
 
Supervised by 
 
Hanna Savolainen-Peltonen, MD, PhD 
Transplantation Laboratory, University of Helsinki and  
Helsinki University Central Hospital 
Helsinki, Finland 
 
and 
 
Professor Pekka Häyry, MD, PhD, FACS (Hon.) 
Transplantation Laboratory, University of Helsinki and  
Helsinki University Central Hospital  
Helsinki, Finland, and 
Department of Surgery and Pathology, 
University of Calgary 
Calgary, AL, Canada 
 
Reviewed by 
 
Professor Timo Paavonen, MD, PhD 
Department of Pathology 
University of Tampere 
Tampere, Finland 
 
and 
 
Docent Maarit Venermo, MD, PhD 
Department of Vascular Surgery 
Helsinki University Central Hospital 
Helsinki, Finland 
 
Discussed with 
 
Professor Markku S. Nieminen, MD, PhD 
Division of Cardiology 
Helsinki University Central Hospital  
Helsinki, Finland 
 
ISBN 978-952-10-5266-8 (pbk.) 
ISBN 978-952-10-5267-5 (PDF) 
ISSN 1457-8433 
http://ethesis.helsinki.fi 
Helsinki University Print 
Helsinki 2009 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To Joakim, Alexander and Iris 
 
 
 
 
TABLE OF CONTENTS 
ORIGINAL PUBLICATIONS    6 
 
ABBREVIATIONS     7 
 
ABSTRACT     8 
 
INTRODUCTION     9 
 
REVIEW OF THE LITERATURE   11 
1. Vasculoproliferative disorders   11 
1.1 Atherosclerosis   11 
1.2 Restenosis   11 
1.3 Transplant arteriosclerosis  13 
2. Pathogenesis of vascular stenosis   14 
2.1 Structure and function of the arterial wall 14 
2.2 The response to vascular injury  15 
2.3 Vascular smooth muscle cells  17 
3. Potential vasculoprotective compounds  19 
3.1 Somatostatin and somatostatin analogs  19
 3.2 Sirolimus   25 
3.3 Imatinib    28 
 
AIMS OF THE STUDY    30 
 
METHODS     31 
1. Rat models of restenosis    31 
2. Drug administration and dosages   32 
3. Cell culture studies    34 
4. Tissue culture studies    36 
5. Histological evaluation    37 
6. Quantitative real-time PCR   39 
7. Complete blood counts     40 
8. Statistical methods    40 
 
RESULTS     41 
1. The in vivo and ex vivo response to vascular injury  41 
2. The vasculoprotective effects of somatostatin and its analogs 42 
3. The vasculoprotective effects of sirolimus and imatinib 45 
 
DISCUSSION     48 
 1. Experimental models of vascular injury  48 
 2. Pathogenesis of vascular disease   50 
 
 
 
 
 3. Therapeutic strategies    51 
  3.1 Somatostatin and somatostatin analogs 51 
  3.2 Sirolimus and imatinib   54 
 
CONCLUSIONS     57 
 
YHTEENVETO (FINNISH SUMMARY)   58 
 
SAMMANDRAG (SWEDISH SUMMARY)   60 
 
ACKNOWLEDGEMENTS    62 
 
REFERENCES     64 
 
 
 
 
 
6
ORIGINAL PUBLICATIONS 
This Thesis is based on the following original publications, which are referred to in the 
text by their Roman numerals: 
 
I Tigerstedt NM, Savolainen-Peltonen H, Lehti S, Häyry P. Vascular cell 
kinetics in response to intimal injury ex vivo. Journal of Vascular Research. 
2009; in press. 
 
II Aavik E, Luoto NM, Petrov L, Aavik S, Patel Y, Häyry P. Elimination of 
vascular fibrointimal hyperplasia by somatostatin receptor 1,4 selective 
agonist in rat. FASEB Journal. 2002; 16: 724-726. * 
 
III Tigerstedt NM, Aavik E, Aavik S, Savolainen-Peltonen H, Häyry P. 
Vasculoprotective effects of somatostatin receptor subtypes. Molecular and 
Cellular Endocrinology. 2007; 279: 34-38. 
 
IV Tigerstedt NM, Aavik E, Lehti S, Häyry P, Savolainen-Peltonen H. 
Synergistic effect of sirolimus and imatinib in preventing restenosis after 
intimal injury. Journal of Vascular Research. 2009; 46: 240-252. 
 
The original publications are reproduced with the permission of the copyright holders.   
* This publication has also been used in the Thesis of Einari Aavik (2005) with the 
permission of the Medical Faculty of the University of Helsinki. 
 
 
 
 
7
ABBREVIATIONS 
ACE angiotensin-converting enzyme 
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ABSTRACT 
Vascular intimal hyperplasia is a major complication following angioplasty. The hallmark 
feature of this disorder is accumulation of dedifferentiated smooth muscle cells (SMCs) to 
the luminal side of the injured artery, cellular proliferation, migration, and synthesis of 
extracellular matrix. This finally results in intimal hyperplasia, which is currently 
considered an untreatable condition. According to current knowledge, a major part of 
neointimal cells derive from circulating precursor cells. This has outdated the traditional in 
vitro cell culture methods of studying neointimal cell migration and proliferation using 
cultured medial SMCs. 
Somatostatin and some of its analogs with different selectivity for the five somatostatin 
receptors (sst1 through sst5) have been shown to have vasculoprotective properties in 
animal studies. However, clinical trials using analogs selective for sst2/sst3/sst5 to prevent 
restenosis after percutaneous transluminal coronary angioplasty (PTCA) have failed to 
show any major benefits. Sirolimus is a cell cycle inhibitor that has been suggested to act 
synergistically with the protein-tyrosine kinase inhibitor imatinib to inhibit neointimal 
hyperplasia in rat already at well-tolerated submaximal oral doses. The mechanisms 
behind this synergy and its long-term efficacy are not known.  
The aim of this study was to set up an ex vivo vascular explant culture model to 
measure neointimal cell activity without excluding the participation of circulating 
progenitor cells. Furthermore, two novel potential vasculoprotective treatment strategies 
were evaluated in detail in rat models of neointimal hyperplasia and in the ex vivo explant 
model: sst1/sst4-selective somatostatin receptor analogs and combination treatment with 
sirolimus and imatinib.  
This study shows how whole vessel explants can be used to study the kinetics of 
neointimal cells and their progenitors, and to evaluate the anti-migratory and anti-
proliferative properties of potential vasculoprotective compounds. It also shows how the 
influx of neointimal progenitor cells occurs already during the first days after vascular 
injury, how the contribution of cell migration is more important in the injury response than 
cell proliferation, and how the adventitia actively contribute in vascular repair.  
The vasculoprotective effect of somatostatin is mediated preferentially through sst4, 
and through inhibition of cell migration rather than of proliferation, which may explain 
why sst2/sst3/sst5-selective analogs have failed in clinical trials. Furthermore, a brief early 
oral treatment with the combination of sirolimus and imatinib at submaximal doses results 
in long-term synergistic suppression of neointimal hyperplasia. The synergy is a result of 
inhibition of post-operative thrombocytosis and leukocytosis, inhibition of neointimal cell 
migration to the injury-site, and maintenance of cell integrity by inhibition of apoptosis 
and SMC dedifferentiation.  
In conclusion, the influx of progenitor cells already during the first days after injury 
and the high neointimal cell migratory activity underlines the importance of early 
therapeutic intervention with anti-migratory compounds to prevent neointimal hyperplasia. 
Sst4-selective analogs and the combination therapy with sirolimus and imatinib represent 
potential targets for the development of such vasculoprotective therapies.  
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INTRODUCTION 
Atherosclerosis and vasculoproliferative disorders are major health concerns, causing 
excess humane suffering, having great economical consequences, and contributing to over 
half of the deaths in the Western World (Braunwald 1997). PTCA is used widely in 
coronary heart disease patients to restore the circulation in atherosclerotic coronary 
arteries; it is, however, complicated by restenosis in 30% to 50% of the patients (Holmes 
et al. 1984). Allograft arteriosclerosis is a major manifestation of chronic rejection, 
limiting the long-term success rate in transplantation. Furthermore, accelerated 
generalized arteriosclerosis contributes to death with a functioning graft (Ojo et al. 2000, 
Kasiske 2001).  
Characteristic to vasculoproliferative disorders is the accumulation of SMCs to the 
inner side of the injured artery, their proliferation, migration, and synthesis of extracellular 
matrix. This results in neointima formation, vascular remodeling, and finally, vascular 
stenosis and ischemia of the tissues perfused by these vessels (Ross 1995). Still, the 
pathogenesis of these vasculoproliferative processes is largely unknown and despite 
extensive efforts to target medial SMCs, the treatment options are limited. However, 
according to current knowledge, a remarkable part of the neointimal cells derive from 
circulating precursor cells (Saiura et al. 2001). This outdates the common in vitro methods 
of studying neointimal cells using cultured medial SMCs, and creates a need for new 
approaches in the research of vasculoproliferative disorders.  
Somatostatin is a vasculoprotective neurohormone that exerts its action through five 
G-protein-coupled receptors (GPCRs), sst1 through sst5 (Lundergan et al. 1991, Reisine 
and Bell 1995). Despite promising results from animal experiments (Lundergan et al. 
1991, Howell et al. 1993), clinical trials evaluating the effects of sst2, sst3, and sst5-
selective agonists octreotide and lanreotide in inhibiting restenosis were not successful 
(Eriksen et al. 1995, von Essen et al. 1997). However, the predominant receptor subtypes 
in rat carotid arteries are sst1 and sst4, and after denudation injury their expression 
increases acutely, whereas the expression of sst2 and sst5 remains low (Khare et al. 1999). 
Also, in human atherosclerotic vessels the predominant receptor subtypes are sst1 and sst4 
(Curtis et al. 2000). Thus, wrong receptor subtypes might have been targeted in the 
clinical trials. 
Sirolimus (rapamycin, Rapamune®) is a powerful antiproliferative agent that inhibits 
cell cycle progression mainly through inhibition of mammalian target of rapamycin 
(mTOR) (Abraham et al. 1996). Sirolimus is currently used in drug-eluting stents for the 
prevention of restenosis after PTCA (Morice et al. 2002). However, the safe use of 
sirolimus-eluting stents (SESs) is limited to very specific vessel and lesion types (Laskey 
et al. 2007). Oral use of sirolimus has been shown to inhibit intimal hyperplasia after 
denudation injury in animal models (Gregory et al. 1993a), but its clinical use has been 
limited by the side-effects associated with the high doses needed for inhibition of 
restenosis (Rodriguez et al. 2003).  
Imatinib mesylate (STI-571, CGP 57148B, Glivec®, Gleevec®) is a protein-tyrosine 
kinase inhibitor in clinical use for cancer treatment. In experimental studies imatinib has 
shown vasculoprotective properties (Myllärniemi et al. 1999, Sihvola et al. 1999). 
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Recently, the combination of imatinib and sirolimus was shown to work synergistically in 
preventing restenosis after balloon-injury in rat already at sub-maximal oral doses 
(Vamvakopoulos et al. 2006). The mechanisms behind this synergy and its long-term 
efficacy are not known. 
The aim of this study was to develop an ex vivo explant culture model to study 
neointimal cell movement, proliferation and differentiation also taking into consideration 
the participation of circulating progenitor cells. Moreover, this model was used together 
with an in vivo experimental restenosis model to evaluate potential new vasculoprotective 
compounds, including sst1- and sst4-selective agonists and the sirolimus-imatinib 
combination. 
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REVIEW OF THE LITERATURE 
1. Vasculoproliferative disorders 
1.1 Atherosclerosis 
Atherosclerosis is a systemic inflammatory disease of the vascular wall (Schwartz et al. 
1985, Ross 1993, 1999). Essential in the development of atherosclerosis is endothelial 
injury, which may be caused by hyperlipidemia, hypertension, or by agents such as the 
herpes simplex virus (Yamashiroya et al. 1988), Chlamydia pneumoniae (Saikku et al. 
1988, Carlsson et al. 1997), or tobacco smoke toxins (Shinton et al. 1989).  
Atherosclerotic leasions consist mostly of inflammatory cells, monocyte-derived 
macrophages, and T lymphocytes. Later on, lipids start to accumulate within the 
macrophages and SMCs are also present in the lesions (Stary et al. 1994). If the 
atherosclerotic changes progress, these initial fatty streaks, which can already be observed 
in early childhood (Napoli et al. 1997), develop into more advanced lesions: plaques with 
a core of lipids and necrotic tissue, covered by a fibrous cap (Stary et al. 1995). Plaque 
rupture or endothelial erosion can initiate thrombosis and arterial occlusion, causing an 
acute coronary syndrome, a stroke, or ischemia of the lower limb, depending on the 
location of the affected artery. 
Well known risk factors for atherosclerosis are e.g. smoking, hyperlipidemia, physical 
inactivity, hypertension, diabetes, aging, male gender and familial predisposition. Primary 
prevention of atherosclerosis includes maintaining a healthy life-style and risk-
intervention, such as blood pressure control, blood lipid management, avoidance of 
tobacco smoke, weight management, diabetes management, and low-dose aspirin for high-
risk patients (Pearson et al. 2002). Secondary prevention in patients with cardiovascular 
disease may also include treatment with clopidogrel or warfarin, angiotensin-converting 
enzyme (ACE) inhibitors or angiotensin receptor blockers, and beta blockers (Smith et al. 
2006).  
In severe cases, surgical revascularisation is indicated to relieve symptoms of ischemia 
and to maintain tissue vitality. The most common treatment choices are angioplasty with 
or without stenting, or bypass surgery. Each of these procedures carry their risks and 
limitations, and none of them can be considered as a permanent cure for atherosclerosis. 
1.2 Restenosis 
PTCA, a procedure where a stenosed or occluded coronary is expanded with an inflatable 
balloon catheter, was first introduced in 1977 (Gruntzig et al. 1977). Similar techniques 
are also used to treat carotid artery stenosis and occlusions in arteries of the lower 
extremities. Restenosis, the re-narrowing of an occluded or stenosed artery treated by 
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angioplasty, is a major limitation for the long-term success of this procedure, and as many 
as 30-50% of vessels are re-occluded six months after PTCA (Holmes et al. 1984, 
Gruentzig et al. 1987, Nobuyoshi et al. 1988).  
In the development of restenosis, a critical event is the mechanical injury to the 
luminal endothelial layer caused by the angioplasty balloon catheter. This triggers a repair 
response characterized by neointimal hyperplasia - the migration and proliferation of 
SMCs and extracellular matrix deposition - and vessel remodeling. This leads to the re-
occlusion, or restenosis, of the vessel, worsening the clinical situation and creating a need 
for either a new procedure or bypass operation.  
The risk factors for restenosis are poorly identified and hard to predict. Patient-related 
factors such as diabetes, hypertension, hypercholesterolemia, renal disease, as well as 
certain lesion and vessel types, have been associated with a higher restenosis risk (Kahn et 
al. 1990, Reis et al. 1991, Hermans et al. 1993, Weintraub et al. 1993).   
A great deal of research has focused on the prevention of restenosis after PTCA (Table 
1). Trials with systemic glucocorticoid therapy, angiotensin converting enzyme inhibitors, 
heparin, and statins have not been successful (Pepine et al. 1990, Faxon 1995, Karsch et 
al. 1996, Serruys et al. 1999). Experiences with devices releasing gamma or beta radiation 
(brachytherapy) at the denudation site have also been discouraging in long-term follow 
ups (Ferrero et al. 2007). Somatostatin-based therapies have exhibited variable success, 
and these therapies are discussed in detail on page 24. 
Table 1 Some experiences from randomized clinical trials on the treatment of restenosis. 
Target/compound Study size 
(patients) 
Restenosis rate at 6 months Reference 
Coagulation pathways    
LMW heparin 625 33% vs 34.4%, p=NS Karsch et al. 1996 
ACE    
Cilazapril 1436 34-40% vs 33%*, p=NS Faxon 1995 
HMG-CoA reductase     
Fluvastatin 1054 28% vs 31%, p=NS Serruys et al. 1999 
Simvastatin + BMS 525 25.4% vs 38%, p<0.005 Walter et al. 2000 
Glucocorticoid receptors    
Methylprednisolone 915 40% vs 39%, p=NS Pepine et al. 1990 
sst2/sst3/sst5    
Lanreotide 553 12% vs 40%, p=0.003 Emanuelsson et al. 1995 
Lanreotide 112 36% vs 37%, p=NS Eriksen et al. 1995 
Octreotide 217 34.3% vs 33.9%, p=NS von Essen et al. 1997 
mTOR    
Sirolimus + BMS 100 12% vs 34.6%**, p=0.009 Rodriguez et al. 2006 
SES 1058 3.2% vs 35.4%**, p<0.001 Moses et al. 2003 
SES  238 0% vs 26.6%, p<0.001 Morice et al. 2002 
* results depended on the drug dosage; ** follow-up at 9 months 
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A significant improvement in the treatment of restenosis was clearly the introduction 
of bare metal stents (BMSs) in 1994. Inserted into the artery during the PTCA to prevent 
negative remodeling and elastic recoil, BMSs help to maintain blood flow through the 
artery (Fischman et al. 1994, Serruys et al. 1994). The success of stenting is, however, 
limited by in-stent restenosis (Fischman et al. 1994, Serruys et al. 1994). Lately, the use of 
stents coated with antiproliferative drugs, such as sirolimus and paclitaxel, have been 
predicted to revolutionize the prevention of restenosis after stenting (Liistro et al. 2002, 
Morice et al. 2002, Grube et al. 2003). However, concern has been raised about the safety, 
long-term efficacy and cost-effectiveness associated with these stent types (Daemen et al. 
2007, Kastrati et al. 2007).   
1.3 Transplant arteriosclerosis 
Transplant arteriosclerosis is the main manifestation of chronic allograft rejection. While 
modern immunosuppressive protocols have raised the one-year graft survival rate to over 
90% for heart and kidney transplants (Orens et al. 2006, Cecka 1997), transplant 
arteriosclerosis remains the major cause for poor long-term success of transplanted organs 
(Sharples et al. 1991, Paul 1993). The incidence of transplant arteriosclerosis is highest in 
cardiac grafts, where changes due to transplant arteriosclerosis can be seen in up to 60% of 
the grafts at one year after transplantation (Julius et al. 2000). Furthermore, in kidney 
transplant recipients accelerated generalized atherosclerosis accounts for a significant 
number of deaths with a functioning graft (Ojo et al. 2000, Kasiske 2001). 
In the development of transplant arteriosclerosis endothelial dysfunction is caused to a 
great extent by a chronic inflammatory injury. The infiltration of inflammatory cells into 
graft arteries results in formation of neointimal fibrosis and vascular remodeling, which 
finally leads to constriction of the vascular lumen and graft ischemia (Uys et al 1984, 
Billingham 1987, Shi et al. 1996a). The changes in the arterial wall resemble those of 
classical atherosclerosis, but they affect the entire length of the vessel, and the lesions are 
diffuse and concentric (Billingham 1989, Shi et al. 1996a), rather than focal and eccentric 
as in atherosclerosis (Fig. 1). Also, lipid accumulations are less common in the early 
stages of transplant arteriosclerosis (Pucci et al. 1990), and the disease progresses faster 
(Paul 1993).  
The risk factors for chronic allograft rejection are still incompletely known, but include 
a high donor age, acute rejection, and a long cold ischemia time (Rao et al. 1990, 
Basadonna et al. 1993, Schwartz et al. 2005). Different immunosuppressive regimens 
improve long-term graft survival, but there is no known effective treatment available for 
transplant arteriosclerosis. 
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Figure 1 A schematic presentation of the differences between atherosclerosis and transplant 
arteriosclerosis. 
2. Pathogenesis of vascular stenosis 
2.1 Structure and function of the arterial wall 
The human arterial wall is composed of three layers, the intima, media, and adventitia. 
The innermost layer, the intima, consists of a single layer of endothelial cells on a basal 
lamina, connective tissue, and the internal elastic lamina. The intima serves as a barrier, 
controlling the movement of cells and other substances from the bloodstream into the 
arterial wall, and further, into other tissues. The endothelium also maintains the inner side 
of the artery in an anti-thrombotic state, a function that can easily be lost as a consequence 
of endothelial injury. Furthermore, endothelial cells serve as regulators of inflammatory 
reactions, and control the growth of other cells types, such as SMCs (Ross and Pawlina 
2006). After vascular injury, re-endothelialization of the site of injury is a crucial process 
in arterial repair (Clowes et al. 1986). 
The middle layer, the media, consists of layers of circumferentially arranged SMCs. 
The media preserves the elasticity of the arteries, enabling them to adjust to blood flow 
pressure. The major task of the differentiated medial SMCs is vasoconstriction and 
vasodilatation. Traditionally, SMCs have been thought to contribute also to arterial wall 
repair, and pathological SMC accumulation is a characteristic feature of intimal 
hyperplasia. SMC activity is regulated by several growth promoters, such as platelet-
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derived growth factor (PDGF) produced by platelets, endothelial cells and macrophages, 
basic fibroblast growth factor (bFGF), and interleukin 1 (IL-1) (Schwartz et al. 1986, Ross 
and Pawlina 2006). 
The outermost layer, the adventitia, consists of connective tissue, and is separated from 
the media by the external elastic lamina. The adventitia with its network of elastic fibers 
and collagen provides support for the arterial wall, helping the vessel to resist the pressure 
of the blood flow. It also contains the vasa vasorum, small blood vessels supplying the 
outer parts of the vessel wall. The inner parts of the vascular wall are supplied from the 
luminal side (Ross and Pawlina 2006). More recently, adventitial myofibroblasts have 
been suggested to contribute actively to neointimal development by proliferating and 
possibly by migrating to the neointima following vascular injury (Scott et al. 1996, Shi et 
al. 1996b, Zalewski and Shi 1997, Oparil et al. 1999, Couffinhal et al. 2001, Frosen et al. 
2001). Adventitial leukocyte accumulation has implied a role for adventitial inflammation 
in vascular lesion formation (Hayashi et al. 2000).  Furthermore, increased numbers of 
adventitial microvessels have been reported in several diseases affecting the vasculature, 
such as vasculitis and hypercholesterolemia (Folkman 1995, Kwon et al. 1998, Kaiser et 
al. 1999). In a porcine model, the number of adventitial microvessels has been shown to 
increase acutely after denudation injury (Pels et al. 1999) and stenting (Cheema et al. 
2006), although the precise role of these vessels in vascular repair is still to be elucidated. 
The adventitia has also been suggested as a site of entrance, or reserve, for neointimal 
progenitor cells (Hu et al. 2004). 
2.2 The response to vascular injury 
Central in our understanding of all vasculoproliferative disorders is the response-to-injury 
hypothesis: injuries to the luminal endothelium trigger a cascade of events eventually 
leading to the development of intimal thickening and vascular remodeling (Libby et al. 
1992, Häyry et al. 1993a, Ross 1995, 1999). This physiological healing process, initially 
designed to guarantee undisrupted blood flow through the artery, can become exaggerated, 
and paradoxically lead to arterial changes causing vessel occlusion and ischemia in the 
area that the vessel is supplying.  
The common denominator for all vasculoproliferative diseases is an injury to the 
endothelium. This results in endothelial dysfunction, increases endothelial permeability, 
and provokes an inflammatory response (Ross 1999). The injury increases the 
adhesiveness of the endothelium for platelets and leukocytes, and induces an upregulation 
of a variety of adhesion molecules. These include selectins (Larsen et al. 1989, McEver et 
al. 1989), integrins (Diacovo et al. 1996, Koyama et al. 1996), platelet-endothelial-cell 
adhesion molecule-1 (Woodfin et al. 2007), intercellular adhesion molecule-1, and 
vascular-cell adhesion molecule-1 (Sluiter et al. 1993, Tanaka et al. 1993), mediating the 
rolling of leukocytes at the site of injury, as well as the adhesion of leukocytes to 
endothelial cells. Thereafter, leukocytes transmigrate into the vascular wall, a process 
mediated by several factors, including the monocyte chemoattractant protein-1 (Rollins 
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1997, Mukaida et al. 1998, Usui et al. 2002), osteopontin (Scatena et al. 2007), 
interleukins (Dinarello 1996), and PDGF (Deuel et al. 1982, Williams et al. 1983).  
Leukocyte activation results in the secretion of metalloproteinases, growth factors, 
inflammatory mediators, and tissue factor. These agents cause inflammatory endothelial 
damage directly, trigger vasoconstriction, promote SMC proliferation, recruit 
mononuclear monocytes, stimulate platelet activation and aggregation, and directly initiate 
the extrinsic coagulation pathway (Bazzoni et al. 1991, Ricevuti et al. 1991). 
Mechanical stretch, exposure to circulating mitogens, as well as growth factors and 
cytokines released from platelets, endothelial cells, and inflammatory cells result in SMC 
migration to the site of injury, and proliferation to form atherosclerotic lesions, restenosis 
or transplant arteriopathy (Libby et al. 1992, Häyry et al. 1993a, Ross 1999). As neointima 
starts to form, the artery can prevent loss of lumen volume by dilatation, a phenomenon 
called remodeling, which to some extent can compensate for the increase in neointimal 
mass (Waller et al. 1991, Mintz et al. 1996). However, if the process of vascular 
inflammation continues, it triggers a positive feedback mechanism, causing further 
accumulation of mononuclear cells and the migration and proliferation of SMCs at the site 
of injury. Eventually the arterial lumen will be critically diminished and blood flow 
subsequently compromised (Ross 1999). 
 
Figure 2 Smooth muscle cell phenotypic switch is a hallmark feature of neointimal 
development. 
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2.3 Vascular smooth muscle cells 
Smooth muscle cells play a pivotal role in vessel wall biology and the development of 
vascular disease, including atherosclerosis, restenosis, and transplant arteriosclerosis. 
SMCs are not terminally differentiated, and can change their phenotype upon local 
environmental cues. Following vascular injury, SMCs accumulate into the intima, migrate, 
proliferate, and synthesize extracellular matrix (Holmes et al. 1984). Neointimal SMCs 
differ in phenotype from medial SMCs, and they are described as dedifferentiated and 
immature cells of a more synthetic phenotype. The synthetic SMCs are characterized by 
their lower levels of SMC contractile proteins and fewer myofilaments, higher synthetical 
activity, and the expression of a large number of proteins that may contribute to the 
development of the neointima (Schwartz et al. 1986, Campbell et al. 1990) (Fig. 2). 
The origin of neointimal SMCs has evoked much controversy. It has long been 
assumed that SMCs migrate to the neointima from the media (Thyberg et al. 1990), and 
that either all medial SMCs (Ross 1999), or only a certain subpopulation of these cells 
(Benditt et al. 1973) are capable of phenotypic modulation. After the neointimal SMC 
population was shown to be heterogenic (Orlandi et al. 1994, Schwartz et al. 1998), 
neointimal cells have been suggested to originate from adventitial fibroblasts that 
transform into myofibroblasts (Shi et al. 1996b, Li et al. 2000), or endothelial cells 
(Gittenberger-de Groot et al. 1999). It has also been proposed that neointimal SMCs 
derive from a subpopulation of immature cells present in the media or adventitia (Majesky 
et al. 1992, Holifield et al. 1996).  
These views have been challenged by reports indicating circulating progenitor cells as 
a potential source of neointimal SMCs (Saiura et al. 2001). In allograft experiments, the 
cells migrating into the vascular intima during chronic rejection in mice, rats, and humans 
are derived from the recipient, not the donor (Hillebrands et al. 2001, Grimm et al. 2001). 
In rodent models using green fluorescent protein or LacZ labeling, or sex-mismatched 
cells, bone marrow stem cells have been shown to contribute to neointimal formation in 
restenosis, allograft arteriosclerosis, and hyperlipidemia-induced atherosclerosis 
(Campbell et al. 2001, Han et al. 2001, Shimizu et al. 2001, Sata et al. 2002, Matsumoto et 
al. 2003, Xu et al. 2004). These results are supported by the notion that adult bone marrow 
contains multipotent cells that can develop into various cell lineages (Pittenger et al. 
1999), and that endothelial progenitor cells can transdifferentiate into SMCs (DeRuiter et 
al. 1997). The proposed origins of neointimal SMCs are summarized in Figure 3.  
However, contradictory evidence also exist regarding the bone marrow origin of the 
circulating precursors (Li et al. 2001, Hillebrands et al. 2002, Hu et al. 2002a, Hu et al. 
2002b). Also the suggested participation rate of these bone marrow precursor cells, as well 
as the percentage of neointimal cells of perivascular origin, vary significantly between 
different reports (Table 2). These discrepancies have been suggested to arise from the 
diversity of neointimal cell origin, and from differences in the models used (Tanaka et al. 
2003). It is also possible that stem cells adopt different mature cell phenotypes by cell 
fusion instead of transdifferentiation (Terada et al. 2002, Ying et al. 2002, Vassilopoulos 
et al. 2003). 
 
 
 
 
 
18
Figure 3 Potential origins of neointimal SMCs. 
Most data on the progenitor origin of neointimal cells derives from animal 
experiments, and it is unclear how well these results can be applied to humans. In animal 
models it has been suggested that bone marrow cells are recruited only when severe 
medial damage occurs (Campbell et al. 2001, Tanaka et al. 2003), and this kind of injury 
should be quite uncommon in the clinic. Nevertheless, human peripheral blood contains 
CD34+ and Flk-1+ precursors capable of differentiating to SMCs (Simper et al. 2002). 
SMCs in coronary atherosclerosis have been shown to be of bone marrow origin (Caplice 
et al. 2003) and vascular progenitor cells are known to exist in human coronary in-stent 
restenosis (Hibbert et al. 2004) and atherosclerotic lesions (Torsney et al. 2007). 
Intracoronary bone marrow cell infusion has evoked interest as a way of improving 
cardiac function after coronary stenting in myocardial infarction. However, in clinical 
trials this approach has been complicated by accelerated atherosclerosis (Kang et al. 2004, 
Mansour et al. 2006).  
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Table 2 Proposed participation rate of progenitor cells of perivascular origin in 
neointimal hyperplasia in various mouse arterial injury models. 
Model/artery Progenitor 
cells 
in neointima 
Progenitor 
cells  
in media 
Days after 
injury 
Reference 
Wire-induced injury     
iliac artery 56%  n.d. 28 Campbell et al. 2001 
femoral artery 56% n.d. 28 Han et al. 2001 
femoral artery 63% 46% 7 Sata et al. 2002 
femoral artery 56% 54% 28 Tanaka et al. 2003 
femoral artery* 39% 61% 28 Tanaka et al. 2003 
Cuff-induced injury     
femoral artery “majority” 0% 7 and 14 Xu et al. 2004 
femoral artery “seldom” 0% 28 Tanaka et al. 2003 
femoral artery* 7% 15% 28 Tanaka et al. 2003 
Ligation-induced injury     
common carotid artery “a few” 0% 28 Tanaka et al. 2003 
common carotid artery* 24% 33% 28 Tanaka et al. 2003 
* ApoE-deficient mice     
3. Potential vasculoprotective compounds 
Potential treatments for vasculoproliferative disorders have been studied extensively. Still, 
no definite cure for atherosclerosis, restenosis, or transplant arteriopathy has emerged. 
This section will review compounds that have shown vasculoprotective properties in this 
thesis study. 
3.1 Somatostatin and somatostatin analogs  
3.1.1 Introduction to natural somatostatin 
Somatostatin was first described in the late 1960s by Krulich and coworkers as well as by 
Hellman and Lernmark separately (Krulich et al. 1968, Hellman and Lernmark 1969). A 
few years later somatostatin was isolated from the hypothalamus (Brazeau et al. 1973). 
This neurohormone, produced by neural, endocrine, and exocrine cells, acts both 
systemically as a true hormone, and locally as a neurotransmitter inhibiting cellular 
proliferation, and modulating hormone and growth factor secretion (Reichlin 1983, 
Mascardo and Sherline 1982, Payan et al. 1984, Patel et al. 1999). The classical effects of 
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somatostatin include inhibition of pituitary gland growth hormone and thyroid-stimulating 
hormone secretion (Brazeau et al. 1973, Reichlin 1983), inhibition of insulin and glucagon 
release from the Islets of Langerhans (Vaysse et al. 1981, Reichlin 1983), and release of 
gastrointestinal hormones from the stomach, gut, and the pancreas (Bloom et al. 1974, 
1975). Somatostatin is also involved as a neuromodulator in the central nervous system 
(Epelbaum et al. 1986, Gillies 1997), and as a vasoconstrictor in the gastrointestinal 
system (Sieber et al. 1992).  
The natural forms of somatostatin, harvested by splicing from prosomatostatin (Hobart 
et al. 1980, Goodman et al. 1980), are somatostatin-14 (SST-14) with equal affinity for all 
somatostatin receptors (Patel and Srikant 1994), and somatostatin-28 (SST-28) with a 
slightly higher affinity for sst5 (Reisine and Bell 1995). Cortistatin is a more recently 
discovered natural somatostatin analog with nanomolar affinity for all somatostatin 
receptors (Fukusumi et al. 1997, Patel et al. 1997). 
Table 3 Properties of human and rat somatostatin receptors.  
Property sst1 sst2 sst3 sst4 sst5 Reference 
Chromosomal 
location 
(human) 
14q13 17q24 22q13.1 20p11.2 16p13.3 Corness et al. 1993 
Demchyshyn et al. 1993 
Yamada et al. 1993 
Panetta et al. 1994 
Chromosomal 
location (rat) 
6q23 10q32.1 7q34 3q41 10q12 Bruno et al. 1992 
Li et al. 1992 
Kluxen et al. 1992 
Meyerhof et al. 1992 
O’Carroll et al. 1992 
Receptor 
identity rat 
vs. human 
94% 94% 83% 88% 82% Patel et al. 1995 
3.1.2 The somatostatin receptor families  
The 7-transmembrane G-protein coupled somatostatin receptors (sst) sst1, sst2A, sst2B, sst3, 
sst4, and sst5, identified in the early 1990s (Yamada et al. 1992a, 1992b, Rohrer et al. 1993, 
Panetta et al. 1994), are encoded by five separate genes, all located on different 
chromosomes (Corness et al. 1993, Demchyshyn et al. 1993, Panetta et al. 1994, Yamada 
et al. 1993) (Table 3). The sst2A and sst2B are thought to arise from alternative splicing of 
the sst2 mRNA (Patel et al. 1993). Based on their structure and functions, the receptors 
have been divided into two families, the sst2/sst3/sst5 and the sst1/sst4 family (Hoyer et al. 
1995, Patel et al. 1995, Reisine and Bell 1995). The homology between rat and human 
somatostatin receptors is high, ranging from 82% (sst5) to 94% (sst1), but there are 
significant species specific variations in sst functions (Patel et al. 1995, Olias et al. 2004). 
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The development of somatostatin receptor agonists and antagonists (Patel and Srikant 
1994, Bass et al. 1996), as well as antibodies for each somatostatin receptor subtype 
(Schulz et al. 2000) has provided more information about the tissue-distribution and 
function of the individual somatostatin receptors. The sst2 is expressed in pancreatic α-
cells (Hunyady et al. 1997) and mediates the inhibition of glucagon release (Rohrer et al. 
1998, Strowski et al. 2000), while sst5 is localized in the insulin-secreting pancreatic β- 
cells (Mitra et al. 1999), and mediates the inhibition of insulin release (Rohrer et al. 1998, 
Strowski et al. 2000). Both receptor subtypes co-localize in pituitary gland somatotrophs 
and mediate the inhibition of growth hormone release (Mezey et al. 1998, Rohrer et al. 
1998, Patel 1999). The other receptor subtypes are believed not to be involved in 
mediating these classical somatostatin effects (Rohrer et al. 1998).  
The role of somatostatin in modulating the immune system has evoked much interest. 
In humans, sst2 has been proposed to modulate the function of inflammatory cells (Patel 
1999), and somatostatin acts as a chemoattractant to sst2-expressing human bone marrow 
and peripheral blood-derived CD34+ cells in vitro (Oomen et al. 2002, Lichtenauer-
Kaligis et al. 2004). In the rat immune system, sst3 and sst4 predominate, while sst2 is 
completely absent (ten Bokum et al. 1999), and targeting through sst4 inhibits a variety of 
inflammatory processes (Helyes et al. 2006).  
3.1.3 Somatostatin receptor signaling 
All somatostatin receptors mediate their effects through inhibition of adenylyl cyclase, 
depression of intracellular cAMP levels (Hoyer et al. 1994, Patel et al. 1994), and 
modulation of mitogen-activated protein kinase (MAPK) (Bito et al. 1994, Cordelier et al. 
1997, Yoshitomi et al. 1997, Florio et al. 1999, Cattaneo et al. 2000). Somatostatin 
receptors also activate phosphotyrosine phosphatase (Florio et al 1994, Reardon et al. 
1997, Sharma et al. 1999), modulate K+ ion channels (Karschin 1995, Kreienkamp et al. 
1997), and couple to phospholipase C (Akbar et al. 1994, Murthy et al. 1996, Lee et al. 
1998, Siehler and Hoyer 1999, Cervia et al. 2003) (Fig. 4). Furthermore, some receptor 
subtypes modulate voltage-dependent Ca2+ ion channels (Fujii et al. 1994, Tallent et al. 
1996, Roosterman et al. 1998), Na+/H+ exchangers (Hou et al. 1994, Schindler et al. 1998, 
Smalley et al. 1998, Chen and Tashjian 1999), and AMPA/kainate glutamate channels 
(Lanneau et al. 1998). 
The expression of somatostatin receptors in different cell types frequently overlap, and 
a single cell can co-express several or even all somatostatin receptor subtypes, suggesting 
that the effects of somatostatin usually are mediated through several ssts working together 
(Patel 1999). In vitro, at least some of the somatostatin receptors are known to undergo 
homodimerization with receptors of the same subtype, or heterodimerization with other 
ssts (Rocheville et al. 2000a, Pfeiffer et al. 2001), or related GPCRs, as opioid (Pfeiffer et 
al. 2002) and dopamine receptors (Rocheville et al. 2000b). Several functional interactions 
between somatostatin receptors have also been reported, such as interactions between sst2A 
and sst5 (Cervia et al. 2003, Sharif et al. 2007), sst2 and sst4 (Moneta et al. 2002), and sst1 
and sst2 (Pavan et al. 2004). When applicable also to in vivo situations, these phenomena 
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can alter ligand binding affinities, function and regulation of the receptors involved, 
further enhancing the functional diversity of somatostatin receptors (Ferone et al. 2007). 
Figure 4 A schematic illustration of the coupling of somatostatin receptors to different 
signaling pathways leading to inhibition of secretion and cell proliferation, and stimulation of cell 
apoptosis. MAPK, mitogen-activated protein kinase. 
3.1.4 Discovery and characterization of synthetic somatostatin analogs 
The use of somatostatin in clinical practice has been limited by its short half-life, <3 min, 
and lack of selectivity (Janecka et al. 2001). Thus, numerous somatostatin analogs with 
improved pharmacokinetics and with different receptor subtype selectivity profiles have 
been developed. 
Octreotide (SMS 201-995), the first long-acting synthetic octapeptide somatostatin 
analog developed into clinical use, exerts its action by binding to sst2, sst3, and sst5, thus 
reducing the secretion of insulin, glucagon, vasoactive intestinal peptide, gastric acid, 
thyroid-stimulating hormone, and growth hormone (Bauer et al. 1982, Lamberts et al. 
1996). Lanreotide (somatuline, angiopeptin, BIM-23014) also shows selectivity for sst2, 
sst3, and sst5, and has actions similar to octreotide. These analogs are in clinical use for the 
treatment of conditions such as acromegaly, for the prevention of complications after 
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pancreatic surgery and esophageal variceal bleedings, and for the symptomatic treatment 
of some hormone producing tumours.  
CH275, the first somatostatin receptor analog targeting the sst1/sst4 receptor family, 
was discovered in the late 1990’s (Liapakis et al. 1996, Patel 1997). Soon thereafter, non-
peptide somatostatin receptor subtype specific agonists for all receptor subtypes were 
described (Rohrer et al. 1998). Non-peptide agonists have evoked much interest due to the 
possibility of developing oral somatostatin therapies.  
3.1.5 Vascular expression of somatostatin receptors  
The reported sst subtype expression in rat and human vascular tissue and cells is 
summarized in Table 4. In rat, all somatostatin receptor subtypes are expressed in vascular 
tissue, but sst2 and sst5 are expressed at much lower levels than the other receptor subtypes 
(Khare et al. 1999). The expression of sst1 peaks acutely after endothelial injury, whereas 
the expression of sst3 and sst4 starts to increase more slowly and remains elevated during 
vessel repair (Khare et al. 1999). In uninjured rat vessels, the somatostatin receptors are 
mostly expressed in the media. After endothelial injury, the expression of sst1, sst3, and sst4 
shifts to neointimal SMCs (Khare et al. 1999). Adventitial cells do not express any 
somatostatin receptors (Khare et al. 1999).  
In normal and diseased human arteries, the predominant receptor subtypes are sst1 and 
sst4, with sst2 expressed only at low levels (Curtis et al. 2000). The expression of sst3 and 
sst5 is absent (Curtis et al. 2000). The endothelium of atherosclerotic arteries has been 
shown to express mostly sst1 (Curtis et al. 2000), while results from studies of sst 
expression in cultured endothelial cells show significant variation. Human umbilical vein 
endothelial cells (HUVECs), have been shown to express sst1, sst2, and sst5 (Adams et al. 
2004, 2005), sst3 only (Florio et al. 2003, Jia et al. 2003), or sst1 and sst4 (Curtis et al. 
2000). In cultured human coronary endothelial cells the reported sst expression ranges 
from the expression of sst4 only (Badway et al. 2004) to the expression of sst1, sst2, and 
sst5 (Yan et al. 2005).  
Cultured human vascular SMCs express sst1 and sst2 (Curtis et al. 2000), while rat 
SMCs express sst4 only (Torrecillas et al. 1999).  
 
 
 
 
 
 
 
 
 
 
24
Table 4 Reported expression of somatostatin receptors in vascular tissue and cells.  
Tissue/Cell type sst1 sst2 sst3 sst4 sst5 Reference 
Human vascular tissue       
normal artery + + 0 + 0 Curtis et al. 2000 
injured artery + + 0 + 0 Curtis et al. 2000 
Rat vascular tissue       
normal artery + + + + +- Reynaert et al. 2007 
normal artery + +- + + +- Khare et al. 1999 
normal artery n.d. + 0 n.d. 0 Chen et al. 1997a 
injured artery + + + + + Khare et al. 1999 
injured artery n.d. + 0 n.d. 0 Chen et al. 1997a 
Human endothelial cells       
HUVECs + 0 0 + 0 Curtis et al. 2000 
HUVECs + + 0 0 + Adams et al. 2004 
HUVECs 0 0 + 0 0 Jia et al. 2003 
proliferating HUVECs + + 0 0 + Adams et al. 2005 
Eahy926* 0 0 + 0 0 Florio et al. 2003 
ECV304** + 0 0 + 0 Curtis et al. 2000 
hCAEC*** 0 0 0 + 0 Badway et al. 2004 
hCAEC*** + + 0 0 + Yan et al. 2005 
Human SMCs       
human aortic SMCs + + 0 0 0 Curtis et al. 2000 
Rat SMCs       
primary rat aortic SMCs 0 0 0 + 0 Torrecillas et al. 1999 
* cell line derived from the fusion of HUVECs with the A549 cell line; ** transformed HUVEC cell line; 
*** human coronary artery endothelial cells; n.d., not defined; 0 = no expression; +- = barely detectable; + =  
clearly expressed 
3.1.6 Vascular effects of somatostatin and its analogs 
In experimental models, somatostatin and its analogs are known to inhibit SMC 
proliferation and migration (Häyry et al. 1993b, Grant et al. 1994, Mooradian et al. 1995, 
Lauder et al. 1997), as well as proliferation of endothelial cells (Lawnicka et al. 2000, 
Adams et al. 2004, 2005). In addition, somatostatin inhibits endothelial cell adhesion 
molecule expression (Badway et al. 2004).  
In 1989, Lundergan and coworkers showed that lanreotide, selective for sst2/sst3/sst5, 
and the related compound BIM23034 inhibited intimal hyperplasia after rat carotid artery 
injury (Lundergan et al. 1989). The results were repeated in different rodent (Lundegan et 
al. 1991, Mennander et al. 1993, Häyry et al. 1993b, Takahashi et al. 1995, Zhao et al. 
1997), rabbit (Howell et al. 1993, Bauters et al. 1994, Foegh et al. 1994) and porcine 
models (Santoian et al. 1993, Hong et al. 1997). An inhibitory effect on intimal 
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hyperplasia after denudation injury has also been reported for octreotide (Yumi et al. 
1997, Yamashita et al. 1999). Furthermore, both compounds have been demonstrated to 
prevent graft vessel disease in rat (Häyry et al. 1993b, Mennander et al. 1993, Bruns et al. 
2000).  
Despite the promising preclinical results, three multicenter trials for the prevention of 
reocclusion or clinical events after PTCA could show only a marginal effect with 
lanreotide (Emmanuelsson et al. 1995, Eriksen et al. 1995) and none with octreotide (von 
Essen et al. 1997). Local drug delivery at the site of injury has been successful with 
lanreotide in a rabbit model (Hong et al. 1993), but not in pigs (Armstrong et al. 2002). 
These results have diminished the enthusiasm for developing somatostatin analogs with 
vasculoprotective properties. Recently, promising results were obtained in a pilot study of 
14 patients treated with a lanreotide-eluting stent (Kwok et al. 2005). Still, no somatostatin 
analogs are currently used routinely in the clinic for the treatment of vasculoproliferative 
disorders.  
The mechanisms behind the potential vasculoprotective effects of somatostatin are not 
fully understood. Somatostatin and sst2/sst3/sst5 analogs have been proposed to interfere 
with SMC proliferation through inhibition of growth factors, such as insulin-like growth 
factor-1 (IGF-1), bFGF, and PDGF-BB (Häyry et al. 1993b, Mennander et al. 1993, Grant 
et al. 1994, Lauder et al. 1997). It has also been suggested that sst2/sst3/sst5 analogs affect 
autocrine and paracrine mechanisms that regulate cell replication (Lundergan et al. 1991), 
or endocrine factors such as growth hormone release (Tiell et al. 1978, Bruns et al. 2000). 
A novel theory is that the vasculoprotective effects of somatostatin are due to anti-
inflammatory effects on the vascular endothelium (Badway et al. 2004, Yan et al. 2005). 
 
3.2 Sirolimus 
3.2.1 Discovery and characterization 
Sirolimus (rapamycin, AY-22,989, Rapamune®) was isolated from a streptomycete found 
in soil samples during a systematical search for new antibiotics (Vezina et al. 1975). The 
samples originated from the Easter Islands, also known as Rapa Nui, which is why the 
compound initially got the name rapamycin. Rapamycin, by generic name sirolimus, was 
originally characterized as an antifungal antibiotic (Sehgal et al. 1975, Vezina et al. 1975). 
The immunosuppressive effects of sirolimus were observed early (Martel et al. 1977), and 
its development as an antifungal drug was stopped. In 1989, the first report was published 
stating that sirolimus could be used for immunosuppression in organ allografting (Calne et 
al. 1989). Almost a decade later the drug entered clinical trials and it proved to be both 
safe and effective as an immunosuppressant after kidney transplantation (Murgia et al. 
1996, Kahan et al. 1998).  
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Figure 5 The sirolimus:FKBP12 complex inhibits growth factor signaling and cell cycle 
progression through inhibition of mTOR. 
3.2.2 Mechanisms of action and clinical pharmacology 
Sirolimus binds to the family of intracellular receptors termed FK binding proteins 
(FKBPs) (Brown et al. 1994, Chen et al. 1994), of which FKBP12 is the most relevant in 
mediating the effects of sirolimus (Jayaraman et al. 1992). The sirolimus:FKBP complex 
is thought to initiate most of its actions through inhibition of mTOR (Chiu et al. 1994, 
Sabers et al. 1995). The inhibition of mTOR modulates several intracellular pathways by 
inhibiting proteins such as the p70S6 kinase (Chung et al. 1992, Price et al. 1992), cycline 
kinase inhibitor p27Kip (Nourse et al. 1994), and phosphorylatable heat stable protein 
(PHAS-1) (Beretta et al. 1996, Brown et al. 1996, Brunn et al. 1997). (Fig. 5). The effects 
on intracellular pathways finally disrupt cell cycle progression from the G1 to the S phase, 
thus inhibiting cell proliferation (Flanagan et al. 1993, Terada et al. 1993). The 
immunosuppressive effect of sirolimus is mediated through inhibition of T cells (Flanagan 
et al. 1993, Terada et al. 1993) and B cells (Aaguaard-Tillery et al. 1994, Kim et al. 1994).  
Sirolimus is a rapidly absorbed drug (maximum blood concentration at 1 hour) with a 
low systemic availability (14%) (Brattstrom et al. 2000, MacDonald et al. 2000). The half-
life of sirolimus is long, 62 hours (Zimmerman and Kahan 1997), and the 2.5-fold 
accumulation of sirolimus blood concentrations for 6 days suggests the need for a loading 
dose that is 3 times higher than the maintenance dose (Zimmerman and Kahan 1997). 
Sirolimus is metabolized by cytochrome P450 (CYP) 3A4 (Sattler et al. 1992, Lampen et 
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al. 1998) and P-glycoprotein (Saeki et al. 1993). The side-effects most commonly 
associated with sirolimus treatment are a decrease in platelet and white blood cell counts 
and hemoglobin, and increased cholesterol values (Murgia et al. 1996, Brara et al. 2003). 
3.2.3 Vascular effects of sirolimus 
In animal experiments oral sirolimus has been effective in preventing intimal hyperplasia 
after ballooning injury, and the side-effects have been minor (Gregory et al. 1993a, Burke 
et al. 1999, Gallo et al. 1999). Treatment with oral sirolimus after implantation of a bare 
metal stent has been shown to reduce restenosis rates (Rodriguez et al. 2003, Waksman et 
al. 2004, Hausleiter et al. 2004, Rodriguez et al. 2006), although contradictory evidence 
also exists (Brara et al. 2003). However, systemic sirolimus treatment has been associated 
with side-effects in more than 50% of the patients (Brara et al. 2003, Waksman et al. 
2004). 
Local therapy with sirolimus-coated intracoronary stents has evoked much interest. 
The first reports on sirolimus-eluting stents in low-risk patients with short de novo lesions 
showed how the application of the stent virtually abolished restenosis (Rensing et al. 2001, 
Sousa et al. 2001a, 2001b). The first larger trials confirmed the benefits of SESs, although 
the results were not quite as impressive as in the pilot studies (Morice et al. 2002, Moses 
et al. 2003).  
Some studies have supported the efficacy of SESs also in high risk patients (Moses et 
al. 2003, Holmes et al. 2004), and in patients with lesions in the left main coronary artery 
(Arampatzis et al. 2003), long de novo lesions in small coronary arteries (Schampaert et al. 
2004), and in patients with in-stent restenosis (Sousa et al. 2003). More recently, these 
more and more common “off-label” indications of SESs have evoked safety concerns, and 
they may associate with a higher risk of death and myocardial infarction (Pfisterer et al. 
2006, Lagerqvist et al. 2007).  Furthermore, SESs have been reported to increase the risk 
of often fatal stent thrombosis (McFadden et al. 2004, Iakovou et al. 2005, Bavry et al. 
2006), and hypersensitivity reactions (Virmani et al. 2004). Characteristic for thrombosis 
associated with drug-eluting stents has been the emergence of very late thrombosis (> 12 
months after PTCA), occuring even later than three years post-PTCA (Daemen et al. 
2007).  
The effects of sirolimus on neointimal hyperplasia are believed to arise from inhibition 
of SMC proliferation and migration (Gregory et al. 1993b, Cao et al. 1995, Marx et al. 
1995, Poon et al. 1996) through modulation of the cycline-dependent kinase p27Kip1 
(Cao et al. 1995, Gallo et al. 1999, Sun et al. 2001). Sirolimus may also exert inhibitory 
effects on circulating smooth muscle progenitor cells and inhibit their differentiation to 
neointimal SMCs (Fukuda et al. 2005). However, sirolimus also suppresses endothelial 
cell proliferation (Akselband et al. 1991) by blocking the p70S6 kinase pathway (Vinals et 
al. 1999), and modulating endothelial progenitor cell proliferation and differentiation 
(Butzal et al. 2004, Chen et al. 2006). These effects might explain the impaired re-
endothelialization associated with SESs (Joner et al. 2006, Luscher et al. 2007).  
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3.3 Imatinib 
3.3.1 Discovery and characterization 
Imatinib mesylate (STI-571, CGP 57148B, Glivec®, Gleevec®) is a protein-tyrosine 
kinase (PTK) inhibitor that was found during a large screening for Abl PTK inhibitors 
(Druker et al. 2000). The most well-known indication for imatinib treatment is chronic 
myelogenous leukemia, characterized by the Bcr-Abl PTK oncoprotein (Konopka et al. 
1984, Daley et al. 1990), which is the target of imatinib treatment. Imatinib is also used in 
the treatment of gastrointestinal stromal tumours (van Oosterom et al. 2001), characterized 
by mutations of c-kit, and occasionally also the platelet-derived growth factor receptor 
(PDGF-R) (Hirota et al. 1998). More recently other indications for imatinib treatment have 
emerged, such as Philadelphia chromosome-positive acute lymphoblastic leukemia, and 
myelodysplastic diseases.  
3.3.2 Mechanisms of action and clinical pharmacology 
PTKs belong to the family of protein kinase enzymes, and they are parts of signaling 
cascades controlling cell growth, adhesion, metabolism, differentiation and apoptosis 
(Robinson et al. 2000). Imatinib inhibits the Abl (Buchdunger et al. 1996, Druker et al. 
1996, Carroll et al. 1997), ARG (Okuda et al. 2001), PDGF-R-α and β (Carroll et al. 1997, 
Buchdunger et al. 2000), and c-kit (Buchdunger et al. 2000, Heinrich et al. 2000) tyrosine 
kinases. However, imatinib has no effect on closely related kinases such as c-Fms, Kdr, 
Flt-1, Tek, and Flt-3 (Buchdunger et al. 2000), v-Fms, c-erbB1, c-erbB2, insulin receptor, 
IGF-1 receptor, Jak-2, and v-Src (Buchdunger et al. 2002). 
Imatinib has an excellent oral bioavailability, and in general treatment is well tolerated 
(Druker et al. 2001a, 2001b).  Metabolization of imatinib occurs mainly by the CYP3A4 
or CYP3A5 (Peng et al. 2005), and it has a half-life of 12-14 hours (Druker et al. 2000). 
The most common side-effects of imatinib 
treatment are nausea, vomiting, oedema and 
muscle cramps; rare side-effects include 
liver toxicity, fluid-retention, neutropenia, 
and thromocytopenia (Kantarjian et al. 
2002, Sawyers et al. 2002, Talpaz et al. 
2002).  
 
 
Figure 6 Molecular structure of imatinib. 
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3.3.3 Vascular effects of imatinib 
Because of its inhibitory effects on PDGF-R, imatinib has also evoked interest as a 
potential vasculoprotective compound. In in vitro settings, imatinib inhibits human and 
rodent vascular SMC proliferation and migration (Myllärniemi et al. 1999, Dudley et al. 
2003, Hacker et al. 2007), without affecting endothelial cell proliferation (Gambacorti-
Passerini et al. 1997, Hacker et al. 2007). In in vivo rodent models, imatinib has been 
shown to inhibit denudation injury-induced neointimal hyperplasia (Myllärniemi et al. 
1999, Wang et al. 2006) as well as transplant arteriopathy (Sihvola et al. 2003), and 
diabetes-associated atherosclerosis (Lassila et al. 2004).  
However, in a standard porcine coronary overstretch model with localized drug 
delivery, imatinib did not prevent neointimal proliferation (Hacker et al. 2007). Also, in a 
pilot clinical trial imatinib failed to prevent recurrent restenosis in patients receiving the 
drug for 2 days prior to, and 7 days after operation (Zohlnhofer et al. 2005). Therefore, 
combination therapies have raised interest, and the addition of sirolimus (Vamvakopoulos 
et al. 2006), or vascular endothelial growth factor-C gene transfer to the treatment protocol 
(Leppänen et al. 2004) has enhanced the vasculoprotective properties of imatinib. 
The vascular effects of imatinib have been thought to arise from its inhibitory effects 
on PDGF-R-dependent processes, such as SMC activation and macrophage infiltration 
(Myllärniemi et al. 1999, Lassila et al. 2004, Leppänen et al. 2004, Hacker et al. 2007). 
Also, c-kit and its ligand stem cell factor (SCF) (Chabot et al. 1988) have been proposed 
as essential in the development of neointimal hyperplasia (Hollenbeck et al. 2004), and it 
has been suggested that imatinib could reduce intimal hyperplasia by modulating vascular 
progenitor cell activity through inhibition of c-kit (Wang et al. 2006). The role of c-Abl 
inhibition has not been determined, but c-Abl is a downstream mediator of PDGF 
signaling (Plattner et al. 2003), and could thus also be a target of imatinib treatment in 
vasculoproliferative disorders. 
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AIMS OF THE STUDY 
The aim of this study was to gain knowledge about the mechanisms of arterial injury 
repair and especially the post-injury mobilization of precursor cells to the vessel wall and 
their differentiation into SMCs that contribute to neointimal hyperplasia. This knowledge 
is essential in the search for novel drug candidates for the treatment of vasculoproliferative 
disorders, and for understanding how these drugs affect the cells in the vascular wall.  
 
The specific aims of the study were: 
 
1. To set up an ex vivo model for neointimal hyperplasia that reflects remodeling after 
intimal injury closer than in vitro SMC culture studies or medial explants and also takes 
into account the participation of precursor cells. 
 
2. To investigate the roles of the five somatostatin receptors in neointima formation 
after denudation injury, and to determine the vasculoprotective properties of sst-agonists 
and their effects on neointimal cell migration and proliferation. 
 
3. To investigate the mechanisms behind the synergistic effect of the sirolimus-
imatinib combination in inhibiting neointimal hyperplasia, as well as the long-term 
efficacy of the treatment. 
 
4.  To identify possible targets for the development of vasculoprotective therapies. 
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METHODS 
1. Rat models of restenosis  
Experimental animals (I-IV) 
Male Wistar rats (250 - 350 g) were purchased from the Laboratory Animal Center, 
University of Helsinki, Finland (II) or from Harlan, Horst, Holland (I, III, IV). The studies 
were approved by the Haartman Institue Ethical Committee for Animal Studies, and the 
permit for animal studies was granted by the Government of the County of Southern 
Finland. Laboratory rats were treated according to the Finnish law on animal rights (9§ 
777/85). All animals received humane care in compliance with the European agreement 
for the use of experimental animals in scientific research, and with the principles of 
Laboratory Animal Care and the Guide for the Care and Use of Laboratory Animals, 
prepared and formulated by the National Institute of Laboratory Animal Resources, 
published by the National Institutes of Health (NIH publication no. 85-23, revised 1996). 
The basic diet of the animals was pellets (Altromin N:o 1314, Standard diet, Chr. Petersen 
A/S, Ringsted, Denmark) and they were given tap water ad libitum. The rats were 
anesthetized with chloral hydrate (240 mg/kg i.p.) and peri- and postoperative pain was 
treated with buprenorphine (0.1 mg/kg s.c., Reckitt & Coleman, Hull, England). The 
permit to use chloral hydrate anesthesia was received from the County veterinarian.  
Rat carotid artery and aortic denudation (I-IV) 
The carotid denudation injury was performed by introducing a 2-French Fogarty balloon 
embolectomy catheter (Baxter Healthcare Corp, Santa Ana, CA) into the common carotid 
artery through the left external carotid artery and inflating the catheter with 0.2 ml of air. 
The inflated catheter resulted in a 0.5 lbs pull force and a balloon size of 4 mm, and the 
catheter was retrieved three times. After removal of the catheter, the external carotid artery 
was ligated and the wound was closed. In the aortic artery denudation model, the 
embolectomy catheter was introduced into the thoracic aorta via the left iliac artery, 
inflated with 0.2 ml air, and passed five times to remove the endothelium. Thereafter, the 
iliac artery was ligated and the wound was closed. Upon sacrifice, the denuded artery was 
removed, and the mid-section of the artery was processed for histology. The rest of the 
artery was either immediately processed for explant cultures, or frozen in liquid nitrogen 
and stored at -70ºC for later RNA isolation.  
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2. Drug administration and dosages 
Somatostatin and somatostatin analogs (II, III, and unpublished results) 
SST-14 (NovaBiochem/Sigma, St. Louis, MO), CH275, and octreotide (NeoSystems 
Strasbourg, France) were diluted in PBS and administered as daily s.c. injections (50-500 
µg/kg), or SST-14 and CH275 by using 7-day or 14-day osmotic minipumps (Alzet, Palo 
Alto, CA) at constant flow rate at equivalent dose levels. The drug treatment was initiated 
at the operation, and control rats received vehicle only. The C18-HPLC profile provided 
by the suppliers showed that the peptides were highly homogenous: SST-14 >99.5%, 
CH275 97%, and octreotide 98.1%. For in vitro studies, the compounds were diluted in 
PBS, and a 25 mM stock solution was prepared. In the in vitro cell line studies, drug 
concentrations of 0.1, 1, 5, and 10 µM were used; in the ex vivo explant studies the drug 
concentrations were 500 µg/kg in vivo and 10 µM in vitro.  
The somatostatin receptor subtype selective agonists were a kind gift from Dr. Susan 
P. Rohrer, Merck & Co., Inc., Rahway, NJ. The agonists were dissolved in DMSO and 
diluted with PBS, and administered at a dose of 300 µg/kg, as recommended by the 
Manufacturer. The agonists were given as a single s.c. injection per day, starting at the day 
of the operation. In the in vitro cell line studies, drug concentrations of 0.1, 1, 5, and 10 
µM were used. In the ex vivo explant studies, the drug concentrations were 300 µg/kg in 
vivo and 10 µM in vitro. For in vitro studies, the compounds were dissolved in DMSO, 
and a 25 mM stock solution was prepared. The final DMSO concentration in the in vitro 
studies was always lower than 0.05%. Selectivities of the different somatostatin analogs 
are summarized in Table 5.  
Table 5  Selectivity of somatostatin analogs in Ki (nM) as measured in CHO-K1 cells.  
Analog sst1 sst2 sst3 sst4 sst5 Reference 
Nonselective natural agonist      
SST-14 0.4-1.1 0.04-1.3 0.7-1.6 0.53-1.7 0.9-2.3 Patel and Srikant 1994 
Rohrer et al. 1998 
sst2/ sst3/ sst5-selective peptide agonist     
Octreotide 230-
>1000 
0.27-2.1 4.4-45 >1000-
2191 
5.6-137 Patel and Srikant 1994 
Yang et al. 1998 
sst1/ sst4-selective peptide agonist     
CH275 3.2 >1000 >1000 4.3 >1000 Patel 1997  
Non-peptide agonists       
L-797,591 1.4 1875 2240 170 3600 Rohrer et al.1998 
L-779,976 2760 0.05 729 310 4260 Rohrer et al.1998 
L-796-778  1255 >10.000  24 8650 1200 Rohrer et al.1998 
L-803,087  199 4720 1280 0.7 3880 Rohrer et al.1998 
L-817,818 3.3 52 64 82 0.4 Rohrer et al.1998 
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Somatostatin plasma levels (II) 
The somatostatin radioimmunoassay (RIA) kit was obtained from Eurodiagnostica 
(Malmö, Sweden). Trifluoroacetic acid (TFA; 1% vol/vol, for CH275) or hydrochloric 
acid (HCL, 0.1 M, for SST-14) was added to each sample and the solution was passed 
over a disposable SepakC18 (Waters, Milford, MA) column. Trapped peptides were eluted 
with 100% methanol. The two peptides were also separated by high-pressure liquid 
chromatography by using a DeltaPak HPI C 18 (Waters) column (2 mm x 15 cm, 5 mm 
particle size). The fractions were collected, evaporated, and redissolved in RIA assay 
buffer and RIA was performed. 
Sirolimus and imatinib (IV) 
Sirolimus (Rapamune oral solution, Wyeth Europa, Berkshire, UK) and imatinib (Glivec 
capsules, Novartis, Basel, CH) were administered orally once a day via a curved gavage 
needle. Sirolimus was stored in the dark at +4°C and used as prescribed; imatinib was 
dissolved in vehicle (PBS) at a concentration of 10mg/mL, stored at +4°C, and used 
within 3 days. The rats were treated with (1) sirolimus 1.0 mg/kg/day, (2) imatinib 10.0 
mg/kg/day, (3) the combination of these, or (4) vehicle. The dosages were based on 
previously performed dose-response analyses (Vamvakopoulos et al. 2006), and sub-
maximal doses were chosen for this study (Fig. 7). Treatment was initiated three days 
before the operation and terminated on day 14 post injury. As in the clinic, the sirolimus-
treatment was started with a loading dose of 3.0 mg/kg/day.   
 
Figure 7 Dose-response curves of sirolimus and imatinib monotreatment, 14 days post injury. 
Submaximal doses were chosen for this study. Modified from Vamvakopoulos et al. J Vasc Res 
2006;43:184-192, with permission of S. Karger AG, Basel, CH. 
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3. Cell culture studies 
Cell lines (II and unpublished results) 
Rat aortic SMCs were isolated from 4-day old Wistar rat aortas using a method modified 
from that of Thyberg and coworkers (Thyberg et al. 1983). The aortas were opened 
longitudinally and the endothelial layer was gently scraped off. The adventitia and media 
were separated, and the medial layer was digested with 0.1% collagenase and DNAse in 
PBS for 30 min at +37ºC. The cells were centrifuged, suspended in culture medium and 
allowed to attach to plastic flasks. Primary cells were used at passage 11-13 for the 
experiments. For identification, the cells were grown on glass slides and stained for 
smooth muscle α-actin (SMA). 
The A10 rat smooth muscle cell line from embryonic thoracic aorta and the MCF-7 
human cell line derived from mammary carcinoma were obtained from the American Type 
Culture Collection (Manassas, VA). 
Human primary skin fibroblasts were isolated from skin tissue of cadaveric human 
donors. The tissue was cut into pieces with scissors and placed in plastic flasks with 
culture medium, allowing fibroblasts to grow out of the tissue pieces. For the experiments, 
primary fibroblasts were used at the 11-13th passage. For identification, the cells were 
grown on glass slides and stained for vimentin, SMA and von Willebrandt factor (vWF). 
All cells expressed vimentin, while none of the cells stained positive for SMA or vWF.  
The culture medium used in experiments with primary SMCs, A10 cells, and primary 
human fibroblasts consisted of Dulbecco's Modified Eagle's medium (DMEM, Gibco, 
Paisley, Scotland) supplemented with 10% Fetal Bovine Serum (FBS, Gibco), 100 IU/ml 
penicillin and 100 µg/l streptomycin, and 2 mmol/ml L-glutamine. For MCF-7 cells, a 1:1 
mixture of DMEM and Nutrient Mixture F-12 (DMEM/F-12, Gibco) with 5% of FBS was 
used. All in vitro studies were done in triplicate and repeated three times. 
Quantitation of cell proliferation in vitro (II and unpublished results) 
In vitro DNA synthesis was measured by tritiated thymidine (3H-TdR, Amersham 
Pharmacia, Amersham, UK) incorporation in response to 5% FBS. Cells were seeded on 
96-well plates (Nunc, Roskilde, Denmark) at a concentration of 5000 cells/well and 
allowed to adhere to the wells in the culture medium supplemented with 5% FBS. The 
next day, the medium was changed to a medium containing 0.5% FBS, and the cells were 
starved for 24-72 hours. Thereafter, the starvation medium was replaced with culture 
medium containing 5% FBS as a stimulant, the 3H-TdR labeling solution, and the serially-
diluted drugs. The cells were allowed to proliferate for 24-72 hours before the content of 
each cell was harvested using trichloroacetic acid (TCA) and natriumhydroxide (NaOH), 
and mixed with OptiPhase Hisafe (LKB-Wallac, Turku, Finland). For the cell toxicity 
assay, the drugs were removed after 48 hours, and the cells were allowed to proliferate in 
culture medium containing 5% FBS without drugs for another 48 hours, before the 
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experiment was terminated. Finally, the amount of radioactive-labelled thymidine 
incorporated to the DNA was measured with a Rackbeta liquid scintillation counter (LKB-
Wallac).  
Quantitation of cell migration in vitro (II and unpublished results) 
Migration was quantitated using Transwell culture chambers (Costar, Cambridge, MA). 
The Transwell system consists of an upper and a lower chamber separated by a 
polycarbonate filter with 8-µm pores. The chambers were first coated with collagen (20 
µg/ml; Rat Tail Collagen, Type 1; Upstate Biotechnology, Lake Placid, NY), at +4ºC for 
24 hours. The cells were seeded in the upper chamber at a concentration of 50,000 
cells/chamber, with 60 ng/ml of the chemoattractant PDGF-BB (Upstate Biotechnology) 
added to the lower chamber, and culture medium without FBS added to both chambers. In 
the upper chamber the cells were allowed to adhere to the filter for 60 minutes, and the 
drugs were then added to the upper chamber. After 24 hours at +37ºC, the cells that had 
migrated to the lower side of the filter were fixed in methanol (+4ºC), stained with 
hematoxylin, and counted microscopically using 400 x magnification (Fig. 8). 
 
Figure 8 Principle of the Transwell migration assay using cultured SMCs. The cells were 
stained with hematoxylin to visualize cell nuclei. 
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4. Tissue culture studies 
Preparation of aortic explants (I-IV) 
As a significant part of neointimal cells have been suggested to originate from circulating 
precursors (Sata et al. 2002), isolated medial SMC cultures might not represent the real 
neointimal cell population, and experiments with these cells might give biased results. 
Therefore, a whole vessel explant assay was set up not to exclude any cell type when 
studying cell migration and proliferation (Fig. 9). The thoracic aortas or carotid arteries of 
injured and control animals were dissected under sterile conditions using a method 
modified of that described by Grunwald and coworkers (Grunwald et al. 1984).  The 
vessels, including all vascular layers, were dissected longitudinally and explants 
measuring 1 x 1 mm were prepared with a McIlwain tissue chopper (Mickle Laboratory 
Engineering, Surrey, UK). The explants were then placed individually into the wells of 
flat-bottomed 96-well plates (Nunc). To keep the explants damp, 20 µl basal medium 
consisting of DMEM (Gibco), 10% FBS (Gibco), 100 IU/ml penicillin and 100 µg/l 
streptomycin and 2 mmol/ml L-glutamine, was added. The plates were placed in a +37°C 
incubator with an atmosphere of 95% air and 5% CO2 for 2 h to allow adherence to the 
tissue culture plastic, whereafter 200 µl of culture medium with or without the drugs 
studied was added to each well.  
 
Figure 9 Principle of the ex vivo explant assay. Whole vessel explants were used in the study 
not to exclude any cell type from the proliferation and migration measurements.The cells growing 
out of the explant have been double stained for SMA (red) and vWF (black), hematoxylin 
counterstain. 
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Measurement of explant outgrowth, migration, and proliferation (I-IV) 
Each well was observed daily and counted as positive for sprouting if cells had grown out 
of the explants. Migration was measured with a calibrated graticule (Olympus, Tokyo, 
Japan) as the distance that the leading edge of sprouting cells in each well had traveled 
from the explant. To measure cell proliferation, the explants were pulsed with 3H-TdR  on 
day 0. On day 2 or 4, the outgrowing cells were detached from the wells with trypsin-
EDTA (Gibco), and the explants were digested with pepsin (Merck, Darmstadt, Germany) 
for 50 min at +37°C. The content of each well was subsequently harvested with a 
Dynatech Harvester (Dynatech Labs, Sussex, UK) and mixed with OptiScint Hisafe 
(LKB-Wallac) before measuring radioactivity with a Rackbeta liquid scintillation counter. 
Limiting dilution assay (I) 
To evaluate the influx of precursors to the vessel wall after injury, explants taken at 15 
minutes, 2, 4, 14, and 21 days post injury were cultured under limiting dilution conditions. 
Samples measuring 1x1 mm, 0.5x0.5 mm, 0.3x0.3 mm and 0.1x0.1 mm were obtained 
using the McIlwain Tissue Chopper and cultured as described above, and the outgrowth of 
cells was measured after 24 hours of culture. Estimates of precursor frequencies in the 
vessel wall at different time points post injury were calculated according to the Poisson 
distribution equation as the slope of a line relating the number of cells per microwell 
(plotted on a linear x-axis) and the percentage of wells with no outgrowth (plotted on a 
logarithmic y-axis) (Dozmorov et al. 2000). 
5. Histological evaluation 
Morphometric analysis (I-IV) 
For evaluation of morphological changes, aortic and carotid midsection specimens were 
fixed in 3% paraformaldehyde, processed for paraffin embedding, and stained with 
Mayer’s hematoxylin and eosin, Masson’s connective tissue, and silver elastic stainings. 
The number of cells in the intima, media, and adventitia, and the number of microvessels 
in the adventitia, were calculated from paraffin cross sections at 400x magnification. The 
areas of the intima and media, and the lumen area and perimeter length were quantitated 
using an Olympus video microscope and the Macintosh NIH-Image Ver.1.62 or Windows 
Image-Pro Plus Ver.4.1.0.0 softwares.  
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Quantitation of cell proliferation in vivo (II and unpublished results) 
Numbers of proliferating cells in vivo were quantitated with the 5-bromo-2’-deoxyuridine 
(BrdU) method. Proliferating cells were labelled with the BrdU solution (3mg/mL, 
Pharmacy of Helsinki University Central Hospital, Helsinki, Finland) intravenously 3 h 
before sacrifice. Incorporation of the labelling reagent was visualized by 
immunohistochemistry (Table 6) using the Vectastain Elite ABC kit (Vector Laboratories, 
Burlingame, CA), according to the Manufacturer’s instructions. Samples were 
counterstained with Mayer’s hematoxylin and eosin, and the number of positive cells was 
counted separately from the intima, media, and adventitia using 400x magnification. 
Immunohistochemistry (I, IV) 
Immunohistochemistry was used to localize different vascular cell markers, and proteins 
coding for the genes quantitated with PCR. A summary of the antibodies and dilutions 
used is presented in Table 6. Paraffin-embedded vessel specimens were deparaffinized 
before the stainings. The stainings were performed using a commercial avidin-peroxidase 
ABC method (Vectastain Elite ABC Kit, Vector Laboratories). The slides were 
sequentially incubated with 0.1% Triton X-100 (5 min, room temperature, RT; Sigma), 
1.5% goat, horse, or rabbit serum (Vector Laboratories; 30 min, RT), primary antibody 
(60 min, RT), biotinylated secondary antibody (30 min, RT), avidin-peroxidase complex 
(Vectastain Elite ABC Kit, Vector Laboratories; 30 min, RT), 0.1% hydrogen peroxide, 
and 3-amino-9-ethylcarbazole (AEC; Sigma), or Nickel-3,3'-diaminobenzidine (Ni-DAB; 
Zymed Laboratories, Inc., San Francisco, CA). Finally, the specimens were counterstained 
with hematoxylin, and coverslips were mounted (Aquamount, BDH Ltd., Poole, UK).  
Controls for antibody staining included replacing the primary antibody with irrelevant 
antibody (M0744, DAKO, Glostrup, Denmark), and omitting the primary antibody. The 
immunostaining was graded separately from the intima, media, and adventitia as follows: 
0 = no visible staining; 1 = some cells with weak staining; 2 = moderate staining with 
multifocal expression; 3 = intense staining throughout the vessel compartment.  
Immunohistochemistry was also used for identification of cells growing out of aortic 
explants. Tissue culture treated glass slides (Becton Dickinson and Co., Franklin Lakes, 
NJ) were coated with collagen (Rat Tail Collagen, Type 1, Upstate Biotechnology) at a 
concentration of 20 µg/ml at +4°C for 24 h. Aortic explants were prepared as described, 
and 3-5 tissue pieces were placed per well to obtain enough material for the stainings. 
Slides were incubated with 50 µl of culture medium in each well in +37˚C for 4 h to allow 
the explants to adhere to the slides. Thereafter, 250 µl of culture medium was added and 
the explants were cultured for 7 days. On day 7, the explants and cells were fixed with 3% 
paraformaldehyde solution for 15 min, whereafter the slides were kept damp with sterile 
PBS at +4˚C until stained. The stainings were performed as described above, and the 
number of positive cells was counted microscopically using 400x magnification.  
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Table 6 Summary of antibodies used for immunohistochemistry. 
Antibody Clone Marker Dilution   Manufacturer 
Mouse monoclonal antibodies 
BrdU Bu20a Proliferating cells 1:20   DAKO, Glostrup, 
Denmark 
ED1 22451D Monocytes/macrophages 1:200 BDPharmingen, San 
Diego, CA 
Flk-1 sc-6251 Hematopoietic/endothelial 
precursors 
1:100 Santa Cruz 
Biotechnology, Inc., 
Santa Cruz, CA,  
LCA M0701 Leukocytes 1:50 DAKO 
SM22α 10H12 SMC differentiation 1:100 Novocastra, 
Newcastle upon 
Tyne, UK 
SMA A2547 SMCs 1:200 Sigma, St. Louis, 
MO 
Vimentin M0725 Cells of mesenchymal 
origin 
1:100 DAKO 
Rat monoclonal antibody    
CD34 
MECA-79 
HECA-452 
sc-52478 
553863 
550407 
Hematopoietic precursors 
High endothelial venules 
High endothelial venules 
1:100 
1:50 
1:50 
Santa Cruz 
BDPharmingen 
BDPharmingen 
 
Rabbit polyclonal antibodies    
BCL2 RDI-BCL2abr Cell survival 1:100 Fitzgerald, Concord, 
MA 
vWF A0082 Endothelial cells 1:100/1:200
 
DAKO 
Chicken polyclonal antibody    
CSRP2 ab14011 SMC differentiation 1:200 AbCam, 
Cambridge, UK 
Goat polyclonal antibody    
CD11b sc-6614 Monocytes, macrophages, 
activated lymphocytes 
1:100 Santa Cruz 
6. Quantitative real-time PCR (QRT-PCR) 
Total RNA was extracted with RNeasy Mini spin columns (Qiagen GMbH, Hilden, 
Germany), and RNA quality was analyzed using an Agilent 2100 Bioanalyzer (Agilent, 
Palo Alto, CA). RNA amplification was performed using an established technique (Wang 
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et al. 2000). Amplified anti-sense RNA was reverse transcribed to cDNA using random 
hexamers and SuperScript II reverse transcriptase (Invitrogen, Carlsbad, CA).  
QRT-PCR analysis was carried out using RotorGene 3000 (Corbett Life Science, 
Sydney, Australia) apparatus and SYBR Green chemistry. The QRT-PCR samples 
consisting of cDNA, both primers, and PCR Master Mix (Applied Biosystems, Foster 
City, CA), were cycled 40 times at the following conditions: denaturation (+95°C, 10 
min), annealing (+60°C, 30 sec), extension (+72°C, 30 sec), and denaturation (+95°C, 15 
sec). The final extension was carried out at +72°C for 10 min. Gene expression levels 
were calculated using RotorGene software (Corbett Life Science) by a comparative 
quantitation algorithm. Primer sequences and accession numbers have been given in the 
original publication (IV). 
7. Complete blood counts (IV) 
Whole blood samples were collected from rats at sacrifice in EDTA tubes for a complete 
blood count analysis, including white blood cell count, white blood cell differential, red 
blood cell count, hemoglobin, hematocrit, platelet count, mean corpuscular volume 
(MCV), mean corpuscular hemoglobin (MCH), and mean corpuscular hemoglobin 
concentration (MCHC). Samples from untreated and unoperated rats were collected to 
obtain normal values. All samples were analyzed at the Central Laboratory of the 
Department of Clinical Veterinary Sciences, University of Helsinki, Finland, with a Cell-
Dyn 3700 System hematology analyzer (Abbott Laboratories, Santa Clara, CA). 
8. Statistical methods 
The data are given as mean±SEM. Limiting dilution analysis was performed with the L-
Calc Software (Stem Cell Technologies, Vancouver, Canada). Statistical analysis of 
parametric comparisons was performed with the Students t test or one-way ANOVA with 
Dunnett’s or Bonferroni correction. In the remaining cases the Mann-Whitney test or 
Kruskal-Wallis test with Dunn correction were applied.  The software used for the 
analyses was Statview 5.0.1 (SAS Institute Inc., Cary, NC). P <0.05 was considered 
statistically significant. 
 
 
 
 
 
41
RESULTS 
1. The in vivo and ex vivo response to vascular injury  
The in vivo response to denudation injury (I) 
The catheter-induced aortic denudation injury resulted in a complete loss of intimal 
endothelial cells. On day 4, the first neointimal cells started to appear, and between days 7 
and 14, the intimal cell number increased markedly, whereafter a plateau was reached. The 
endothelial injury did not induce changes in the medial cell number at any time point. 
However, between days 4 and 14, the adventitial cell number increased up to 4-fold 
compared to control and returned to control level by day 28 post injury (Fig. 10). Also, the 
adventitial microvessel number increased 4-fold between days 7 and 21, whereafter their 
number returned back to the pre-denudation level.  
For further evaluation of the response to denudation injury, aortic samples were stained 
for the endothelial cell-specific antigen vWF, the SMC-specific SMA, the cytoskeletal 
protein vimentin, and the progenitor cell markers Flk-1 and CD34. In un-injured vessels, 
vWF was predominantly expressed in the intima. Re-endothelialization of the neointima 
started between days 4 and 14 post injury, and was nearly completed by 90 days post 
injury.  
Medial cells expressed SMA both in the resting state and post injury. The first SMA-
positive neointimal cells were detected at 7 days after injury. On day 14, the whole 
neointima stained faintly positive. Thereafter, the staining intensity increased, and from 21 
to 28 days post injury, both the neointima and media showed strong immunoreactivity for 
SMA.   
Vimentin was expressed in all layers of the resting vascular wall. Early after injury, the 
expression was mainly localized to the adventitia. However, the intensity of adventitial 
staining declined by day 21, and thereafter, vimentin was predominantly expressed in the 
neointima.  
Flk-1 was expressed in the adventitia and occasionally in intimal cells of un-injured 
vessels. After injury, the first neointimal cells stained positive for Flk-1, and at later time-
points staining was seen in all vascular layers. Our attempts to show CD34 protein in any 
of the samples failed. 
The ex vivo response to denudation injury (I, II) 
An ex vivo aortic explant model was established to evaluate the migration, proliferation, 
and maturation of neointimal cells in an in vitro setting without excluding neointimal 
precursor cells.  
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The percentage of wells with sprouts, the migration distance, and the frequency of 
progenitor cells increased significantly in samples obtained 2-14 days post denudation, 
peaking on day 4 post injury (13-fold, 3.5-fold, and 8.5-fold changes compared to control, 
respectively). DNA synthesis in explants, as measured by 3H-TdR incorporation, peaked 
on day 7 after denudation injury (6771±452 CPM vs. 3700±466 CPM, p<0.0001 
compared to control). Thereafter, the explant activity declined and returned to the control 
level by day 21 after injury (Fig. 10). 
The cells growing out of vascular explants were identified by immunohistochemistry. 
The majority of the outgrowing cells expressed SMA and a significant part also expressed 
vWF, vimentin, or the progenitor cell markers Flk-1 and CD34. Only 0.05±0.015% of the 
cells were positive for the mononuclear phagocyte antigen ED1 and 2.6±2.5% for the 
leukocyte antigen LCA. Double immunohistochemistry showed that many of the cells co-
expressed SMA, vWF, vimentin, or LCA.  
The cellular responses in carotid and aortic explants were also compared and they were 
shown to be similar (II). As it was difficult to obtain enough tissue material from carotid 
arteries, only aortic explants were used in the subsequent studies (I, III, IV). 
Figure 10  Kinetics of intima and adventitia cell numbers in vivo after denudation injury 
compared to progenitor cell numbers and cell migration/proliferation in ex vivo explants.  
2. The vasculoprotective effects of somatostatin and its analogs 
Effects of somatostatin and its analogs on neointimal hyperplasia (II, III) 
The nonselective SST-14, administered as daily s.c. injections, significantly decreased the 
intimal cell number (p=0.001 compared to control), intimal area (p=0.03), and reduced the 
intima-media ratio (p=0.014). CH275, selective to sst1 and sst4, offered superior 
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vasculoprotection, and dose-dependently decreased the intimal cell number (p=0.0001 
compared to control), intimal area (p= 0.0002), intima-media ratio (p=0.0009), as well as 
the adventitial cell number (p=0.006). CH275 also decreased the number of replicating 
cells in the intima, as measured by BrdU-incorporation (p=0.004). Octreotide, selective to 
sst2, sst3, and sst5, decreased only the intimal cell number (p=0.01).  
SST-14 and CH275 had no effect on neointimal hyperplasia when administered as 
continuous infusions through osmotic minipumps.  
To investigate if discontinuation of the medication would cause a rebound effect, rats 
received SST-14, CH275, and octreotide for 14 days post injury, whereafter the 
medication was replaced with vehicle for another 14 days. In this setting, no rebound 
effect on intimal hyperplasia was observed with CH275 and octreotide, while SST-14 lost 
its efficacy. 
As CH275, selective to sst1 and sst4, proved to be the most effective compound in 
inhibiting neointimal hyperplasia, we continued to investigate the individual 
vasculoprotective properties of sst1 and sst4 with subtype specific agonists. Daily s.c. 
injections of the sst4-selective agonist remarkably increased lumen size (p<0.01), and 
reduced the intima-media ratio (p<0.05), the intimal cell number (p<0.05), and intimal 
area (p<0.05). The sst1-selective agonist increased lumen size (p<0.05 compared to 
control), while the other sst-selective agonists had no effects on the parameters measured. 
None of the subtype-selective agonists affected cell proliferation in vivo (Tigerstedt NM et 
al. unpublished results). 
Effects of somatostatin and its analogs on ex vivo explants (II, III) 
The explant model was used to evaluate the effect of the drugs ex vivo. The explants were 
obtained two days post-injury and outgrowth, migration, and proliferation were evaluated 
after 48 h of culture. The animals were given SST-14, CH275, or octreotide in vivo at a 
dose of 500 µg/kg, and the treatment was continued in vitro at a dose of 10 µM, or with 
vehicle. CH275 and octreotide inhibited cell outgrowth and migration, but not cell 
replication in the post injury tissue fragments. SST-14 did not have significant effects on 
any of the measured parameters. 
In the explant experiment with the subtype-selective sst agonists, the drugs were 
administered in vivo only (III). Only the sst4-selective ligand inhibited explant outgrowth 
by 42% and migration by 60% (p<0.01 and p<0.05, respectively). The sst5-selective 
agonist had a small inhibitory effect on explant outgrowth (p<0.05), but none of the other 
agonists had any effect on the parameters measured. 
In vitro cellular responses to drug treatment (II, III, and unpublished results) 
The effects of the somatostatin analogs were also tested using the 3H-TdR replication and 
Transwell migration assays with primary rat SMCs and the A10 rat SMC line and, for 
comparison, human skin fibroblasts and the MCF-7 human breast cancer cell line. SST-14, 
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CH275, and octreotide did not affect the proliferation of the cell lines used. Only the sst1-
selective compound showed a significant antiproliferative effect on all the cell lines at the 
10 µM concentration (Fig. 11A, Tigerstedt NM et al. unpublished results).  
 
Figure 11 Effect of the sst1-selective analog on the proliferation of SMCs, MCF-7 cells, and 
fibroblasts. 
However, the 10 µM dose was not toxic, as the inhibitory effect of the sst1-selective 
compound was reversible, and there was no difference in the viability of the drug-treated 
cells compared to the non-treated cells after 48 h of culture in vitro (Fig. 11B, Tigerstedt 
NM et al. unpublished results).  
In the Transwell chamber assay, none of the drugs had any effect on the PDGF-BB (60 
ng/ml) induced migration. 
Effects of somatostatin and its analogs on rat weight and drug levels (II, III) 
SST-14 and the somatostatin analogs were well-tolerated, and there were no weight 
differences between vehicle and drug-treated rats. 
The serum levels of SST-14 and CH275 were evaluated as the drugs inhibited 
neointimal hyperplasia only when administered as daily injections, but not when 
administered through osmotic minipumps. SST-14 concentration peaked at 360 pmol/L, 
and CH275 concentration at 280 pmol/L after 200 µg/kg s.c. injections. Estimated in vivo 
half-lives were 20 min for SST-14 and 90 min for CH275. Using minipumps, serum levels 
of approximately 110 pmol/L were obtained at about 10 h after installation of the pump, 
and they remained on this level throughout the 7-day lifetime of the pump. With the 
highest drug dose, 500 µg/kg, high (up to 1200 pmol/L) but short lasting peaks were 
observed. 
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3. The vasculoprotective effects of sirolimus and imatinib 
Long-term effects of sirolimus and imatinib on neointimal hyperplasia (IV) 
When given individually, only sirolimus showed moderate vasculoprotective effects 
throughout the observation period while imatinib lost its effect after 14 days post-injury. 
However, early combination treatment with sirolimus and imatinib, discontinued at day 14 
post-injury, showed a sustained therapeutic synergy that was statistically significant even 
at 90 days with 64% suppression in intimal nuclei number (p<0.0001 compared to 
control), 82% suppression in intimal area (p=0.0048), and 13% increase in perimeter 
length (p=0.0103) (Table 7). No changes were seen in medial and adventitial nuclei 
numbers or areas.  
Table 7  Effects of drug treatment on intimal cell area, cell number, and perimeter length 
after denudation injury. 
 Control Imatinib   Sirolimus Combi 
Intimal area (square pixels x103) 
Day 14 74.4±11.9 46.4±6.0 31.1±5.7* 18.0±1.4† 
Day 40 74.0±14.0 59.8±12.5 30.0±4.2* 12.8±3.5† 
Day 90 85.2±15.4 61.7±13.7 41.4±6.8* 15.4±9.4† 
Intimal cell number 
Day 14 872.2±38.1 585.6±41.0‡ 371±43.9‡ 142.8±8.2‡ 
Day 40 803.8±77.2 653.3±80.6 366.1±54.4‡ 159.6±20.2‡  
Day 90 844.6±94.1 639.6±61.3 509.8±56.8† 301.8±64.9‡ 
Perimeter length (pixels x102) 
Day 14 43.3±0.7 45.7±1.4 49.0±1.2† 49.2±0.7† 
Day 40 47.1±0.6 48.3±1.6 50.7±1.4 51.3±0.9† 
Day 90 47.6±1.1 49.4±1.9 51.0±0.9 53.8±1.2* 
The data are expressed as mean±SEM (n=5-7). *p<0.5, †<0.01, ‡p<0.001, compared to control. Combi = 
combination therapy 
Effects of sirolimus and imatinib on ex vivo explants (IV) 
To study the effect of sirolimus, imatinib, the combination of these, or vehicle on ex vivo 
explant outgrowth, migration, and proliferation, the treatment was initiated 3 days before 
the operation and discontinued at sacrifice. Both imatinib and sirolimus inhibited explant 
outgrowth by 71% and 85%, respectively (p<0.0001 compared to control), and migration 
by 76% and 84%, respectively (p=0.0005 and p=0.0002). However, the effect of the 
combination treatment was superior, and it inhibited explant outgrowth by 93% and 
migration by 96% (p<0.0001). All treatments also reduced explant proliferation 
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(p<0.0001); here sirolimus alone was the most effective treatment causing a 97% 
reduction in proliferation. 
Effects of sirolimus and imatinib on vascular gene expression (IV) 
Gene and protein expression in the vascular wall were assessed to evaluate possible 
mechanisms behind the effects of the different treatments.  
The combination treatment with sirolimus and imatinib inhibited the early 
downregulation of the SMC markers SM22α and CSRP2, which are associated with the 
differentiated SMC phenotype. By immunohistochemistry, the SMC marker proteins were 
localized to the media on day 4 post injury, and on day 40 to the media and neointima.  
Both the sirolimus and the combination treatments were associated with an increased 
expression of the anti-apoptotic BCL-2 mRNA on day 4 post injury compared to the 
control level. This was reflected mainly by increased BCL-2 immunoreactivity in the 
media and adventitia. On day 40 post injury, a downregulation of the BCL-2 mRNA was 
observed in all treatment groups. This was reflected by a lower BCL-2 staining intensity in 
the media. 
Following denudation injury and a complete removal of the intimal endothelial layer, 
the vWF mRNA was highly downregulated on days 2-5 in control rats, and returned to the 
pre-injury level on days 5-7 when the reendothelialization of the intima begun. Sirolimus 
treatment upregulated the early vWF mRNA expression, while imatinib treatment 
repressed it, and the expression remained at the control level in the combination therapy 
group. At day 4 post injury, vWF protein expression was localized to the first cells re-
appearing to the intima, as well as to the adventitial microvessels. While the vWF mRNA 
expression remained at the control level in the imatinib group on day 40 post injury, 
sirolimus and combination treatment both downregulated the vWF expression. This was 
observed as a delayed reendothelialization of the neointima by 62% (p=0.0469, compared 
to control) in the sirolimus treatment group, and by 54% (p=0.0423, compared to control) 
in the combination treatment group. 
Effects of sirolimus and imatinib on rat weight and complete blood counts 
(IV) 
The imatinib, sirolimus, and the combination therapy were well-tolerated, and there were 
no weight differences between vehicle and drug-treated rats. Complete blood counts were 
determined at days 4, 14, 40, and 90 post injury to gain mechanistic insights and to 
monitor the well-being and post-operative recovery of the animals. Blood hemoglobin 
levels decreased at day 4 after the operation in all but the combi group. By day 40 post-
injury, the hemoglobin levels in all treatment groups had returned to pre-operation and 
pre-treatment level. 
Blood leukocyte counts increased in the control group peaking at day 14 post injury. 
The same trend was seen in all other groups, except in the combi group, where the 
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leukocyte count remained at the pre-injury level. The elevation in leukocyte concentration 
was mainly due to an increased number of neutrophils and lymphocytes. There were no 
significant differences between the treatment groups at the later time points. 
There was a tendency towards a rise in thrombocyte counts post injury at 4 days in all 
groups, except in rats treated with the combination of sirolimus and imatinib. At days 14, 
40, and 90 post-injury, there were again no significant differences between the treatment 
groups.  
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DISCUSSION 
Neointima formation after vascular injury is a complex interplay of different cell types, 
growth factors, cytokines, and signaling cascades. Despite extensive efforts to reveal the 
exact mechanisms behind this process and to develop therapeutic interventions, much is 
still unknown, and the treatment options are scarce. 
1. Experimental models of vascular injury 
In vivo models of intimal hyperplasia 
Animal models are essential in restenosis research. Different stages of neointimal 
hyperplasia are impossible to study in humans, as the study material usually consists of 
post-mortem findings showing only severe disease. Furthermore, animal models are 
essential when screening for potential new drug candidates. The rat model of intimal 
hyperplasia after denudation injury used in this Thesis (I-IV) has several benefits. The 
model is well characterized, and it has been used extensively for several decades (Clowes 
et al. 1986, Myllärniemi et al. 1997). It is feasible, economical, reproducible, and 
technically relatively easy and fast to perform, which makes it less susceptible to 
methodological problems and biases. The rat vessel develops substantial levels of 
neointima, which is quite essential when studying intimal hyperplasia, but something often 
not seen in the standard mouse vascular injury models (Iafrati et al. 1997, Xu et al. 2004).  
However, the rat model has some significant shortcomings. First, the vessel structure 
in rat differs from that in humans. Human vessels have a more prominent intima, while the 
rat vessel intima consists of a single layer of endothelial cells only (Sims 1989, Du Toit et 
al. 2001). Second, rats do not develop atherosclerosis. In clinical conditions, vascular 
injury includes a response to a long-term stress caused by factors such as low-grade 
inflammation, diabetes, dyslipidemia, and toxins. These are all absent in laboratory rats. 
Third, in the rat denudation injury model, the vascular injury is performed on a previously 
healthy artery, while the artery undergoing surgical interventions in the clinical setting is 
already diseased. Fourth and last, the therapeutic targets – signaling pathways, growth 
factors and receptors – might not be identical in rat and man. Nevertheless, if these 
limitations are acknowledged, the rat denudation model can provide important information 
about vasculoproliferative disorders and potential treatments for the prevention of such 
diseases. 
In vitro and ex vivo models of intimal hyperplasia 
Targeting the proliferation and migration of medial SMCs has been studied extensively. 
Traditionally, this has been performed using SMC cell lines or primary SMCs of medial 
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origin, and these cells have been observed in in vitro experimental set-ups, such as the 
Transwell chamber migration assay or 3H-TdR replication experiments also used in this 
thesis study (II, Tigerstedt NM et al. unpublished results). Still, the efforts to target medial 
SMCs have not resulted in findings that could offer a solution for the treatment of 
vasculoproliferative disorders. 
In 1984, Grunwald and Haudenschield observed that an in vivo intimal injury could 
stimulate cells to grow out of medial explants in ex vivo cultures (Grunwald and 
Haudenschild 1984). Later, it was also observed that hypertension increased proliferation 
in explants prepared in the same way (Grunwald et al. 1987).  Whole vessel cultures were 
used in the 1960s and 1970s for various purposes (Wexler et al. 1967, Larrue et al. 1977), 
but later on the adventitia and intima were systematically dissected out (Kenagy et al. 
1996, Sun et al. 2001, Kenagy et al. 2002), as neointimal cells were believed to originate 
from the media. 
However, as a significant part of neointimal SMCs have recently been shown to derive 
from precursor cells of perivascular origin, the role of isolated medial SMC cultures or 
medial explants in restenosis research can be questioned. The limited liability of SMC 
cultures was also observed in this study. All of the somatostatin analogs tested, SST-14, 
octreotide, CH275, and the sst subtype-specific agonists, failed to prevent the migration of 
SMCs in Transwell cell chambers, and these results did not correlate with the potential of 
the compounds to prevent intimal hyperplasia in vivo (II, III, Tigerstedt NM et al., 
unpublished results). The same observation was made with the SMC replication 
experiments. Of the compounds mentioned above, only the sst5-selective analog inhibited 
cell proliferation, but again, this finding could not be related to in vivo events (II, III, 
Tigerstedt NM et al., unpublished results). 
To compensate for the limitations of the in vitro experiments, an ex vivo explant assay 
was set up. In this assay, the entire vessel wall was used for the culture to also include 
precursors migrated into the adventitia or neointima. A vascular injury was initiated in 
vivo, and later 1 x 1 mm punch explants were prepared for tissue culture, and monitored 
for cell outgrowth, migration, and proliferation (I). As evaluated by 
immunohistochemistry, the cells growing out of the explants showed characteristics of 
undifferentiated cells, as they co-expressed SMA, vWF, LCA, or vimentin. Furthermore, 
almost half of the cells expressed the progenitor cell marker Flk-1, and 14% were positive 
for the stem cell marker CD34 (I). Results from somatostatin studies using the ex vivo 
explant assay showed a much higher correlation with the in vivo findings, compared to 
traditional in vitro studies (II, III). Despite the possibility of some contamination with 
irrelevant cells types, the ex vivo explant assay offered a more versatile approach to 
neointimal cell studies than the in vitro SMC studies or medial explant cultures. 
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2. Pathogenesis of vascular disease 
Vascular SMC migration and proliferation 
The major cell type in neointimal lesions is the SMCs that migrate into the intima, 
proliferate, and produce extracellular matrix, thus forming a neointima. The role of cell 
proliferation in this process has evoked controversies. In animal models, only a small 
fraction of SMCs proliferate in response to vascular injury, and migration seems to be 
more important than proliferation (Clowes and Schwartz 1985, Du Toit et al. 2001). 
Furthermore, cell proliferation is low in specimens retrieved from human restenotic 
atherectomy tissue or in-stent restenosis sites (Moreno et al. 1999, O’Brien et al. 2000).  
These observations are consistent with the results of this thesis study. In the ex vivo 
explant model, the migratory response to vascular injury far outweighed the proliferatory 
response (I). Also, the potential vasculoprotective somatostatin analogs that could inhibit 
intimal hyperplasia in vivo, showed antimigratory properties in the ex vivo model. At the 
same time, their antiproliferative capacity, as measured by in vivo BrdU incorporation, or 
in vitro / ex vivo 3H-TdR incorporation, was scarce, or close to non-existent (II, III, 
Tigerstedt NM et al. unpublished results).  
Stem cells in vascular disease 
The recent finding that neointimal SMCs may stem from perivascular progenitor cells has 
evoked much interest and speculations on the origin of the progenitor cells, as well as of 
their relative contribution to arterial repair compared to SMCs derived from the vessel 
wall. The highly differing results might be explained by SMCs having several sources of 
origin (Tanaka et al. 2003). It has also been proposed that the role of perivascular 
progenitors might vary depending on the severity of the vascular injury (Campbell et al. 
2001, Tanaka et al. 2003). With the experimental setup used in this thesis study, it was 
unfortunately not possible to address the question on whether neointimal cells derive from 
the bone marrow or other perivascular tissue.  However, in general, there seems to exist a 
wide acceptance for the perivascular origin of at least a significant part of the neointimal 
SMCs (Campbell et al. 2001, Sata et al. 2002, Tanaka et al. 2003, Xu et al. 2004).  
The time-window for precursor cell influx is not known, and both the intima and 
adventitia have been suggested as routes for precursor cell entry to the vessel wall 
(Campbell et al. 2001, Saiura et al. 2001). In a rat denudation injury model, the 
proliferative activity of cells as measured by BrdU-incorporation has been observed to 
shift from the adventitia to the neointima by 14 days post-injury (Frosen et al. 2001; I). 
Also, in mice carotid allografts, the first cells of perivascular origin have been observed in 
the adventitia at 7 days after transplantation, whereas they do not appear in the neointima 
or media until one week later (Matsumoto et al. 2003). Moreover, the number of 
adventitial microvessels has been shown to increase acutely after vascular injury (Pels et 
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al. 1999, Cheema et al. 2006), reflecting adventitial activity and remodeling. Precursor 
cells have also been suggested to store up in the adventitia in aortic roots (Hu et al. 2004). 
In this study, the influx of precursor cells occurred early after endothelial removal, 
mostly on days 2-4 (I). In concert with previous findings, formation of the neointima was 
preceded by adventitial activation, an increase in adventitial microvessel number, as well 
as a displacement of vimentin and Flk-1 expression from the adventitia to the neointima 
(I). Thus, the results of this Thesis further emphasize the role of the adventitia in the injury 
response and indicate that the adventitia might serve as a reserve, or a point of entry to the 
vascular wall for SMC precursors (I). 
3. Therapeutic strategies to overcome restenosis 
3.1 Somatostatin and somatostatin analogs 
Somatostatin exerts its inhibitory action on growth hormone secretion, cellular 
proliferation, as well as different growth factors and cytokines through five GPCRs. Due 
to its limited bioavailability, a short half-life of less than 3 minutes, and multiple functions 
in different organs, numerous somatostatin analogs with improved pharmacokinetics and 
receptor selectivity and affinity have been developed both for therapeutic and 
investigational use. In the late 1980s, the vasculoprotective properties of somatostatin 
were observed (Lundergan et al. 1989). However, promising preclinical results with 
sst2/sst3/sst5 analogs in the prevention of intimal hyperplasia could not be repeated in 
clinical trials (Emmanuelsson et al. 1995, Eriksen et al. 1995, von Essen et al. 1997), 
reducing the enthusiasm for the development of somatostatin-based therapies for the 
prevention and treatment of vasculoproliferative disorders.  
Somatostatin receptor expression in vascular tissue 
The pattern of somatostatin receptor expression shows high variation between different 
tissues and cell types (Hofland and Lamberts 2001, Reubi et al. 2001), and the literature is 
very inconsistent when it comes to sst receptor subtype expression profiles, especially as 
far as vascular cells are concerned. This has partly been suggested to arise from 
differences in detection sensitivity between the methods used (Moller et al. 2003). There 
are also significant species-dependent differences between the sst expression profiles 
(Olias et al. 2004), as well as variation between individuals (Adams et al. 2005, Taniyama 
et al. 2005). Furthermore, somatostatin receptor expression can change during disease 
progression (Khare et al. 1999), as a result of ligand binding (Rocheville et al. 2000a), or 
cell replication (Adams et al. 2005). The interpretation of results on sst expression 
obtained from different experimental setups in different species is thus a challenging task. 
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Most investigations on sst expression in human endothelial cells have been made on 
HUVECs, and although the results differ highly, HUVECs have been shown to express all 
five ssts (Curtis et al. 2000, Florio et al. 2003, Jia et al. 2003, Adams et al. 2004, 2005). 
Also in human coronary artery endothelial cells, a cell type closer to our target cells, the 
reported sst expression ranges from the expression of sst4 only (Badway et al. 2004) to the 
expression of sst1, sst2, and sst5 (Yan et al. 2005). Endothelial cell heterogeneity most 
likely accounts for some of the observed differences in sst expression (Conway et al. 
2004), as well as changes in receptor expression profiles that can occur during cell culture 
in late passages (Curtis et al. 2000). Human vascular SMCs have been shown to express 
sst1 and sst2 in vitro (Curtis et al. 2000). Finally, in human arteries in vivo, the predominant 
sst receptor subtypes in both normal and atherosclerotic vessels are sst1 and sst4 (Curtis et 
al. 2000). 
In rat arteries, the expression of all ssts has been reported (Khare et al. 1999, Reynaert 
et al. 2007). However, most of the sst expression has been located to medial and 
neointimal SMCs, not to endothelial cells. Rat aortic SMCs in vitro have been shown to 
express mainly sst4 (Torrecillas et al. 1999), although experiments with sst2/sst3/sst5-
selective agonists suggest that cultured SMCs can express at least sst5, possibly also sst2 
and sst3 (Grant et al. 1994, Lauder et al. 1997). 
Taking into consideration the variety of sst receptor expression, it is fully possible that 
vascular cells are capable of expressing all sst subtypes, but that their expression varies at 
different stages of vascular disease. Still, in the rat model of vascular injury used in this 
thesis study (II, III), the predominant somatostatin receptor subtypes expressed post injury 
are sst1, sst3, and sst4 (Khare et al. 1999). This suggests that somatostatin action on rat 
vascular injury is mediated through one of these receptors. This is also in agreement with 
the results obtained in this Thesis (II, III). The sst1/sst4 subtype-selective analog CH275 
and the sst4-selective L-803,087 significantly inhibited neointimal hyperplasia after 
vascular injury. Similar to octreotide and lanreotide in clinical studies, the subtype-
selective analogs for sst2, sst3, and sst5 failed to shown any vasculoprotective characters 
and the sst1-selective analog had only a moderate effect on neointimal hyperplasia. The 
results from the ex vivo tissue cultures support these findings, and together all suggest 
targeting through sst4 when aiming at vasculoprotection with somatostatin analogs (II, III). 
Even if the homology between rat and human somatostatin receptors is high, ranging 
from 82% (sst5) to 94% (sst1) (Patel et al. 1995), there are significant species dependent 
differences in binding affinities between different somatostatin receptors for somatostatin 
analogs. As an example, the rat sst5 has a 160-fold higher affinity for octreotide than the 
human sst5 (O’Carroll et al. 1994). The affinities of the non-peptidyl sst subtype-specific 
ligands used in this study (III) were originally tested with human receptors (Rohrer et al. 
1998), but they have successfully been used also in rat studies (Parmar et al. 1999, 
Pittaluga et al. 2000, Blake 2001, Cowles et al. 2002, Elberg et al. 2002, Emery et al. 
2002, Stark and Mentlein 2002, Cervia et al. 2003). Also the sst1/sst4 ligand used, CH275, 
has been widely and successfully used in rat models (Chen et al. 1997b, Traina et al. 1998, 
Mastrodimou et al. 2004, Marazioti et al. 2005). Still, results obtained with rat models can 
not be transferred to man directly, and will require verification in clinical trials before any 
further conclusions can be made. 
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The vasculoprotective effects of somatostatin and its analogs 
Several mechanisms have been suggested to account for the vasculoprotective effect of 
somatostatin. It has been shown that sst2/sst3/sst5 analogs inhibit SMC proliferation and 
migration through inhibition of growth factors, such as PDGF, IGF-1 and bFGF (Häyry et 
al. 1993b, Mennander et al. 1993, Grant et al. 1994, Lauder et al. 1997), or by affecting 
autocrine and paracrine mechanisms that regulate cell replication (Lundergan et al. 1991). 
Also, a direct sst2-mediated inhibition of vascular SMC proliferation has been suggested 
(Grant et al. 1994, Grant and Caballero 2002). Furthermore, sst2/sst3/sst5 analogs have 
been shown to inhibit neointimal hyperplasia through inhibition of growth hormone 
release (Tiell et al. 1978, Bruns et al. 2000).  
Very little is known about vascular effects mediated through sst4. Somatostatin has 
been suggested to exert an anti-inflammatory effect on the vascular endothelium through 
sst4 (Badway et al. 2004). In our model of vascular injury the importance of this 
mechanism was most likely limited, as the endothelium was completely removed by a 
balloon catheter, and the first neointimal cells appeared at day 4 post injury, while the 
explants for the ex vivo cultures were obtained already at day 2 post injury (II, III). Also, 
in the in vivo experiments, drug treatment was stopped on day 14 post injury (II, III), when 
the reendothelialization was not completed (I).  
The role of sst4 in mediating an anti-migratory effect on neointimal cells has 
previously been implicated based on the increase in sst4 expression post injury at the time 
when the migratory activity in the vessel wall is strongest (Khare et al. 1999). In 
agreement with this finding, both the sst1/sst4-selective analog CH275, and the sst4-
selective ligand L-803,087 showed anti-migratory properties in an ex vivo setting with 
vessel cultures (II, III). It can be speculated that as the ex vivo anti-migratory effect was 
seen early during the time-point of progenitor cell influx (I, II, III), targeting through sst4 
would inhibit the migration of these cells to the vascular wall. 
In the in vitro thymidine incorporation assay, the sst1 analog showed antiproliferative 
properties on a primary rat SMC cell line, and the A10 cell line from rat embryonic 
thoracic aorta. An anti-proliferative effect was also seen to a lesser extent on a human skin 
fibroblast and the MCF-7 human mammary adenocarcinoma cell lines, both of which have 
been reported to express all five ssts (Hagstromer et al. 2006, Watt and Kumar 2006). The 
results were only seen with quite high doses of the analog, 5 and 10 µM, but toxicity was 
not observed, as withdrawal of the drug resulted in a catch-up in proliferation (Tigerstedt 
NM et al. unpublished results). Nevertheless, the high doses of the sst1 analog needed for 
the inhibition of proliferation might refer to an off-target response. In the ex vivo explant 
assay, none of the tested compounds inhibited cell proliferation (II, III). 
Although there is still much to learn about the biology of somatostatin and 
somatostatin receptors, the results in this study (II, III) are in agreement with the current 
literature. The predominant sst receptors in the rat model of vascular injury used in this 
thesis are sst1, sst3 and sst4 (Khare et al. 1999). The first somatostatin study showed the 
superiority of an sst1/sst4-selective agonist in inhibiting intimal hyperplasia both in vivo 
and ex vivo, and narrowed down the interest to two sst subtypes: sst1 and sst4 (II). When 
targeted separately, only sst4 showed vasculoprotective properties, and this effect seems to 
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be mediated through inhibition of migration rather than proliferation (II, III). These results 
offer an explanation for why sst2/sst3/sst5 analogs failed to prevent restenosis in clinical 
trials. Already a brief 14-day treatment post injury was sufficient for vasculoprotection (II, 
III), providing evidence for the importance of early therapeutic intervention when aiming 
to prevent intimal hyperplasia.  
As the classical somatostatin effects are mediated through sst2/sst3/sst5, the most 
common adverse effects with analogs targeting these receptors are gallstones, diarrhea, 
nausea, abdominal pain, and hypoglycemia or hyperglycemia. During long-term octreotide 
treatment gallstones can occur in as many as 50% of the patients treated (Dowling et al. 
1992). It would thus be important to be able to bypass these adverse effects by selective 
receptor targeting. However, if the vasculoprotective properties of somatostatin are 
mediated through sst4 (II, III), we might speculate that by targeting through sst4 only, 
adverse effects associated with sst2/sst3/sst5 analogs could be avoided. 
3.2 Sirolimus and imatinib 
Sirolimus-eluting stents significantly reduce restenosis rates after PTCA (Morice et al. 
2002, Moses et al. 2003, Morice et al. 2007). However, the currently considered safe use 
of SESs is limited to very specific vessel and lesion types and requires prolonged anti-
thrombotic medication (Laskey et al. 2007), and it is thus not a treatment suitable for all 
patients or all vascular fibroproliferative disorders. Oral sirolimus treatment has been 
limited by side effects related to the high drug doses needed for restenosis inhibition 
(Waksman et al. 2004).  
As imatinib inhibits SMC proliferation and vascular progenitor cell action, but not the 
proliferation of endothelial cells (Gambacorti-Passerini et al. 1997, Wang et al. 2006, 
Hacker et al. 2007), it possesses many qualities of a theoretical “ideal” antirestenosis drug. 
In rodent models, imatinib has shown some vasculoprotective potential, most likely 
through its inhibitory effects on the PDGFR and c-kit tyrosine kinases (Myllärniemi et al. 
1999, Sihvola et al. 2003, Lassila et al. 2004, Wang et al. 2006). These affect SMC 
accumulation, migration, proliferation, dedifferentiation, as well as stem cell proliferation, 
adhesion, and mobilization (Ferns et al. 1991, Jawien et al. 1992, Leary et al. 1992, 
Fleming et al. 1993, Levesque et al. 1995, Kenagy et al. 1997).  
The clinical experience on imatinib and its vasculoprotective properties is limited to a 
pilot study, where imatinib failed to prevent recurrent in-stent restenosis in a group of 180 
patients at 1 year after stent implantation (Zohlnhofer et al. 2005). In that study, imatinib 
treatment was initiated 2 days before repeat intervention, and continued for 10 days. This 
lack of long-term vasculoprotection by short-term interference with PDGF signaling has 
been implied in studies with other PDGF inhibitors as well (Leppänen et al. 2000). These 
findings are in line with the results in this thesis study: short-term imatinib treatment did 
not produce long-term inhibition of intimal hyperplasia, and a catch-up in intimal growth 
was seen already 3 weeks after discontinuation of the treatment (IV). Thus, imatinib 
monotherapy might not be powerful enough for the prevention of neointimal hyperplasia, 
at least with the brief early exposure as the treatment strategy. 
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The synergistic effect of sirolimus and imatinib 
Optimal long-term vasculoprotection might require simultaneous targeting of several 
signaling pathways involved in neointimal development. Several drug combinations have 
been suggested for dual therapies. In the clinic, sirolimus has been successfully combined 
both with CsA (Kahan et al. 1998), and tacrolimus (McAlister et al. 2000) to improve the 
outcome of allograft rejection, and with fluvastatin in rodent models (Gregory et al. 2001). 
In preclinical cancer treatment studies, imatinib has been combined with sirolimus to 
overcome drug resistance due to new mutations in Bcr-Abl (Ly et al., 2003, Mohi et al. 
2004).  
In a rat denudation injury model, inhibiting cell cycle progression with sirolimus and 
the c-kit and PDGF-R kinases with imatinib for the first 14 days after denudation injury 
resulted in a synergistic suppression of intimal hyperplasia (Vamvakopoulos et al. 2006). 
In this thesis study it was further shown that this well-timed and well-tolerated oral 
combination treatment with submaximal doses of sirolimus and imatinib produced a long-
term synergistic suppression of intimal hyperplasia, reducing intimal area by 80% even at 
90 days after injury (IV).  
The mechanisms behind the synergistic effect have not been established earlier. With 
gene expression analyses, we were able to show that the combination treatment 
upregulated the mRNA expression of SMC markers CSRP2 and SM22α (IV). This most 
likely reflects an inhibition of SMC dedifferentiation, or a promotive effect on SMC 
integrity, as both CSRP2 and SM22α are associated with the maintenance of SMCs in a 
differentiated, contractile, and passive state (Louis et al. 1997, Zhang et al. 2001, Owens et 
al. 2004, Wei et al. 2005). The phenotypic switch of SMCs to dedifferentiated secretory 
SMCs is a hallmark feature of intimal hyperplasia (Shanahan et al. 1993, Shanahan et al. 
1994), and in vehicle-treated rats, the expression of both CSRP2 and SM22α mRNA was 
sharply downregulated immediately after denudation injury (IV). Furthermore, stabilizing 
cell integrity and inhibiting SMC apoptosis have recently been proposed as a strategy to 
prevent intimal hyperplasia (Sukhanov et al. 2007). As the combination treatment also 
upregulated the anti-apoptotic BCL2 gene, this finding might be of significance for the 
vasculoprotective effects of this treatment. 
Several growth factors are involved in the control of the SMC phenotypic switch, 
including transforming growth factor-ß (TGF-ß) (Muto et al. 2007), and PDGF-BB 
(Dandre and Owens 2004, Liu et al. 2005). As sirolimus increases TGF-ß expression 
(Wang et al. 1996), and imatinib inhibits PDGF receptor kinases (Buchdunger et al. 2000), 
the effects of the combination treatment on SMCs might be related to growth factor 
mediated signaling events.  
Compared to the other treatment groups the combination treatment was also more 
efficient in inhibiting neointimal cell migration in the ex vivo explant model, while 
sirolimus showed the highest antiproliferative capacity (IV). As the contribution of cell 
migration may be more important in the development of intimal hyperplasia than that of 
cell proliferation (I; Du Toit et al. 2001), the anti-migratory properties of the combination 
treatment might explain its superior in vivo effects. 
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Sirolimus is a powerful antiproliferative agent. However, as it inhibits neointimal 
hyperplasia, it also interferes with the vascular healing process after stenting by inhibiting 
endothelial cell proliferation and slowing down reendothelialization, thus increasing the 
risk for stent thrombosis (Virmani et al. 2004, Iakovou et al. 2005).  In the study with the 
combination of sirolimus and imatinib (IV), one concern was how this combination would 
affect reendothelialization post injury. As expected, a downregulation of the endothelial 
marker von Willebrandt factor mRNA expression was seen at 40 days post injury in the 
rats receiving sirolimus treatment, and the number of vWF-positive luminal cells was 
reduced. In the combination treatment group, an even stronger downregulation of vWF 
mRNA expression was observed. PDGF-R kinase-directed compounds, such as imatinib, 
should not affect endothelial cells (Levitzki 2005). On the contrary, inhibition of PDGF-
R-ß has been shown to promote reendothelialization (Noiseux et al. 2000), and it could 
thus have been anticipated that the addition of imatinib to the sirolimus treatment would 
enhance reendothelialization. However, as sirolimus inhibits endothelial progenitor cell 
proliferation (Fukuda et al. 2005), and imatinib also targets the SCF/c-kit pathway (Wang 
et al. 2006), the combination therapy might have an additive effect on recruitment, 
proliferation, or migration of endothelial progenitor cells. 
In concert with previous findings (Aavik et al. 2005), the most intense gene expression 
changes were seen during the first weeks post-injury (IV). Furthermore, the influx of 
neointimal progenitor cells occurs already at 2-4 days post injury (I). Thus, as shown with 
both the combination of sirolimus and imatinib (IV), as well as with sst analogs targeting 
sst4 (II, III), an early timed therapeutical intervention is crucial when aiming at 
vasculoprotection. 
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CONCLUSIONS 
The following conclusions can be drawn from this study: 
 
1. Whole vessel vascular explant cultures can be used to study the migration and 
proliferation of neointimal cells in response to in vivo denudation injury, without 
excluding the participation of neointimal progenitor cells. This assay model can also be 
used to evaluate the anti-migratory and anti-proliferative properties of potential 
vasculoprotective compounds.  
 
2. In rat, the vasculoprotective effects of somatostatin are mediated through sst4, and 
this effect is mediated through inhibition of cell migration rather than proliferation. Thus, 
clinical trials with sst2/sst3/sst5-selective analogs failed because the wrong receptor 
subtypes might have been targeted. Targeting through sst4 should be considered when 
developing somatostatin-based vasculoprotective therapies.  
 
3. The combination of sirolimus and imatinib at well-tolerated submaximal doses 
provides a long-term synergistic inhibition of neointimal hyperplasia in rat. The 
mechanisms behind the synergy most likely include inhibition of post-operative 
thrombocytosis and leukocytosis, inhibition of neointimal cell migration to the injury-site, 
and maintenance of cell integrity by inhibition of apoptosis and SMC dedifferentiation.  
 
4. The outer vascular layer, adventitia, is more than just a passive supportive structure, 
and it contributes actively in vascular repair. The influx of circulating progenitor cells 
occurs already during the first days post-injury, and the migration of neointimal cells to 
the site of injury is a hallmark feature of neointimal hyperplasia. Thus, inhibition of cell 
migration is more important than interfering with cell proliferation.  
 
5. Together these findings underline the importance of early therapeutic intervention 
with anti-migratory compounds in preventing intimal hyperplasia. The vasculoprotective 
potential of sst4 analogs and the combination of sirolimus and imatinib could serve as a 
basis for future therapeutic considerations. 
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YHTEENVETO (FINNISH SUMMARY) 
Verisuoniahtauman pallolaajennuksen jälkeen jopa 30-50% laajennetuista suonista 
ahtautuu uudelleen 3-6 kuukauden sisällä suonten sisäkerroksen, intiman, paksuuntumisen 
seurauksena. Valtimoiden uudelleen ahtautumisen, eli restenoosin kehittymisessä 
avainasemassa ovat erilaistumattomat sileälihassolut, jotka aktivoituvat verisuonivaurion 
seurauksena ja kerääntyvät hallitsemattomasti verisuonen sisäpinnalle. Aikaisemmin 
sileälihassolujen uskottiin vaeltavan intimaan verisuonen keskikerroksesta, mediasta. 
Viime aikoina julkaistu tutkimustieto kuitenkin osoittaa näiden solujen olevan ainakin 
osittain peräisin verenkierron kantasoluista, mikä on luonut uusia haasteita valtimoiden 
uudelleen ahtautumisen tutkimukselle, koska sileälihassolujen käyttäytymistä on 
perinteisesti tutkittu valtimon keskikerroksesta peräisin olevien sileälihassoluviljelmien 
avulla.  
Somatostatiini on viiden G-proteiinikytketyn reseptorin (sst1-sst5) kautta vaikuttava 
solukasvua rajoittava hormoni. Ihmisen verisuonissa on lähes yksinomaan 
reseptorialatyyppejä 1 ja 4 ja rotalla näiden reseptoreiden määrän on todettu lisääntyvän 
äkillisesti verisuonivaurion jälkeen. Eläinmalleissa somatostatiini estää pallolaajennuksen 
jälkeistä restenoosia. Kliinisissä kokeissa sst2/sst3/sst5 -selektiiviset analogit oktreotidi ja 
lanreotidi eivät kuitenkaan pystyneet merkittävästi estämään sepelvaltimoiden restenoosia.   
Sirolimuusi on mTOR-estäjä, jonka on osoitettu sekä eläinmalleissa että kliinisissä 
kokeissa estävän pallolaajennuksen jälkeistä verisuonten uudelleen ahtautumista. 
Systeemisen sirolimuusihoidon ongelmana on kuitenkin ollut lääkkeen huono siedettävyys 
annoksilla, joita vaaditaan hoitotehon saavuttamiseksi. Imatinibi on tiettyjen syöpien 
hoidossa käytetty tyrosiinikinaasi-estäjä, jonka on eläinkokeissa osoitettu omaavan myös 
suotuisia verisuonivaikutuksia. Rotalla imatinibin ja sirolimuusin yhdistelmähoito estää 
synergistisesti pallolaajennuksen jälkeistä verisuonten uudelleenahtaumaa jo hyvin 
siedetyillä matalilla annoksilla. Synergian taustoja tai pitkäaikaistehoa ei kuitenkaan 
tunneta. 
Tämän väitöskirjatyön tavoitteena oli kehittää ex vivo – kudosviljelymenetelmä, jonka 
avulla pystyttäisiin tutkimaan valtimon uudelleenahtaumaan osallistuvien solujen 
toimintaa sulkematta pois kantasolujen vaikutusta prosessissa. Tavoitteena oli lisäksi 
selvittää somatostatiinianalogien sekä sirolimuusi-imatinibi -yhdistelmähoidon 
verisuonivaikutuksia. Ex vivo kudosviljelmien lisäksi työssä käytettiin soluviljelmiä, rotan 
kaulavaltimon ja aortan pallolaajennusmalleja, immunohistokemiaa sekä kvantitatiivista 
real-time PCR-menetelmää.  
Tämä tutkimustyö osoittaa, miten ex vivo –kudosviljelymenetelmää voidaan käyttää 
verisuonen uudelleenahtaumaan osallistuvien solujen tutkimiseen (I), sekä lääkeaineiden 
verisuonivaikutusten arviointiin (I-IV). Työssä havaittiin, että erilaistumattomat kantasolut 
hakeutuivat verisuoneen heti ensimmäisinä verisuonivaurion jälkeisinä päivinä, ja että 
solujen vaeltaminen (migraatio) verisuonen seinämässä oli verisuonivaurion 
korjausprosessin kannalta solujen jakautumista (proliferaatio) tärkeämpää (I). Lisäksi 
adventitian todettiin osallistuvan aktiivisesti verisuonivaurion korjaamiseen (I).  
Somatostatiinianalogeista sst1/sst4 -selektiivinen CH275 esti rotan verisuonten 
uudelleenahtaumaa merkittävästi sst2/sst3/sst5 -selektiivisiä analogeja tehokkaammin (II). 
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Reseptoriselektivisten lääkeaineiden avulla osoitettiin somatostatiinin verisuonia 
suojaavan vaikutuksen välittyvän erityisesti sst4:n kautta (III). Tämä tapahtui pääosin 
estämällä solujen vaeltamista, ei niinkään solujen jakautumista. Väitöskirjassa osoitetaan 
lisäksi, että oikein ajoitettu sirolimuusin ja imatinibin yhdistelmähoito säilytti tehonsa 
myös pitkäaikaisseurannassa. Yhdistelmähoidon vaikutus perustui leikkauksen jälkeisen 
trombosytoosin, leukosytoosin sekä solujen vaeltamisen estoon, sileälihassolujen 
erilaistumisasteen ylläpitämiseen sekä apoptoosin estoon (IV).  
Väitöskirjatyö osoittaa restenoosiin osallistuvien solujen ilmaantuvan verisuonen 
seinämään heti ensimmäisinä verisuonivaurion jälkeisinä päivinä ja solujen vaeltamisen 
olevan tässä prosessissa solujen jakautumista tärkeämpää. Tämän vuoksi verisuonten 
uudelleen ahtaumista on yritettävä hoitaa solujen vaeltamista estävillä lääkeaineilla 
välittömästi verisuonivaurion jälkeen. Sekä sst4–selektiiviset lääkeaineet että sirolimuusin 
ja imatinibin yhdistelmä ovat varteenotettavia vaihtoehtoja tämänkaltaisten 
verisuoniselektiivisten lääkeaineiden kehittelyssä.  
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SAMMANDRAG (SWEDISH SUMMARY) 
Efter ballongdilatation av aterosklerotiska artärer återförträngs 30-50% av blodkärlen 
inom 3-6 månader på grund av förtjockning av artärväggens innersta lager, intiman. En 
central roll i återförtjockningen av artärer, eller restenosen, utspelas av dedifferentierade 
glatta muskelceller, som okontrollerat ansamlas på insidan av den skadade artärväggen. 
Tidigare uppgavs glatta muskelceller migrera till intiman från artärens mellanlager, 
median. Nyligen har det dock påvisats, att en betydande del av de glatta muskelceller som 
ansamlas vid artärskadan kan härstamma från cirkulerande stamceller. Det här har medfört 
nya utmaningar för forskningen av restenos, då man traditionellt undersökt glatta 
muskelcellers beteende med hjälp av cellodlingar som härstammat från artärens 
mellanlager.  
Somatostatin är ett neurohormon som agerar via fem G-proteinkopplade receptorer 
(sst1-sst5) och hämmar celltillväxt. I människans blodkärl förekommer nästan enbart sst1 
och sst4, och hos råttor har mängden av de här receptortyperna konstaterats öka akut efter 
en blodkärlsskada. I djurmodeller har somatostatin och dess analoger kunnat hämma 
artärers återförtjockning efter ballongdilatation. I kliniska försök med de sst2, sst3 och sst5-
selektiva somatostatinanalogerna oktreotid och lanreotid kunde dock just ingen 
blodkärlsskyddande effekt påvisas.  
Sirolimus är en mTOR-hämmare som minskar återförtjockning av artärer efter 
ballongdilatation både i försöksdjursmodeller och i kliniska studier. Hos människor har 
dock sirolimusvården associerats med med märkbara biverkningar med de höga doserna 
som krävts för att den önskade vårdeffekten kunnat uppnås. Imatinib är en 
tyrosinkinashämmare som används vid vård av vissa cancertyper. Hos råttor har imatinib 
haft blodkärlsskyddande effekter. Därtill har man kunnat påvisa, att kombinationen av 
imatinib och sirolimus hämmar återförträngning av artärer synergistiskt redan med 
vältolererade submaximala doser av läkemedlen. Kombinationsmedicineringens långtida 
effekt och mekanismerna bakom synergin är dock okända. 
Målet med den här avhandlingen var att utvecka en ex vivo–vävnadsodlingsmetod, 
med vilken man kunde undersöka funktionen av celler som deltar i restenos utan att 
utesluta inverkan av stamceller. Målet var därtill att utforska de blodkärlsskyddande 
effekterna bakom somatostatinanaloger och kombinationsbehandlingen med sirolimus och 
imatinib. Förutom ex vivo-vävnadsodlingar användes cellodlingar, ballongdilatations-
modeller med råttor, immunohistokemi samt kvantitativ real-time PCR. 
Den här avhandlingsstudien påvisar hur en ex vivo–vävnadsodlingsmetod kan 
användas för att studera de celler som deltar i artärers återförtjockning (I). Modellen kan 
även användas för att utvärdera potentiella läkemedelsbehandlingars antimigratoriska och 
antiproliferativa effekter (I-IV). Därtill påvisas, att stamceller söker sig till artärväggen 
redan under de första dagarna efter blodkärlsskadan, att cellmigration spelar en viktigare 
roll än cellproliferation under artärväggens läkningsprocess och att adventitian aktivt 
deltar i restenos (I).  
Den sst1/sst4-selektiva somatostatinanalogen CH275 kan hämma artärers 
återförtjockning efter ballongdilatation betydligt bättre än sst2/sst3/sst5-selektiva 
somatostatinanaloger (II). Med hjälp av analoger selektiva för var sin sst specificeras 
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därtill, att somatostatinets blodkärlsverkan medieras i första hand via sst4. Den här 
effekten sker främst via inhibition av cellmigration, inte cellproliferation (III). Dessutom 
påvisar avhandlingsarbetet, att effekten av en tidig och kortvarig kombinationsbehandling 
med vältolererade submaximala doser av sirolimus och imatinib är långvarig. 
Kombinationsbehandlingens effekt grundar sig på hämmandet av post-operativ 
trombocytos och leukocytos, samt hämmandet av cellmigration och glatta muskelcellers 
dedifferentiation och apoptos (IV).   
Avhandlingen påvisar, att neointimans stamceller strömmar in i blodkärlsväggen redan 
under de första dagarna efter blodkärlsskadan och att cellmigration spelar en större roll än 
cellproliferation i återförtjockningsprocessen. Därför bör försök att hindra artärers 
återförtjockning påbörjas omedelbart efter blodkärlsskadan med antimigratoriska 
läkemedel. Somatostatinanaloger selektiva för sst4 och kombinationen med sirolimus och 
imatinib kan representera sådana behandlingsalternativ.  
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